pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: Phase 2

Sep 18, 2023

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Sep 13, 2023

Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease

Sep 12, 2023

Anokion Announces Clinical Progress with KAN-101 and ANK-700

Sep 11, 2023

Autobahn Therapeutics Completes Dosing in its Phase 1 Multiple-ascending Dose Study of ABX-002 for Major Depressive Disorder and Reports Company Progress

Sep 6, 2023

ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Hospitalized Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Sep 6, 2023

Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Sep 6, 2023

Imvax Provides Corporate Update

Aug 28, 2023

Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Aug 25, 2023

XyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at the European Society of Cardiology (ESC) Congress 2023

Aug 14, 2023

Microbion to Present Design of Ongoing Phase 2 Study Treating Diabetic Foot Ulcer Infections at the 2023 Military Health System Research Symposium

Aug 14, 2023

EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies

Aug 8, 2023

Imvax Announces Publication in Journal for ImmunoTherapy of Cancer Showing IGV-001 Can Induce Clinically Relevant Anti-Cancer Immune Responses in Glioblastoma via Immunogenic Cell Death

Aug 1, 2023

ReAlta Life Sciences Doses First Patient in Phase 2 STAR-Study of RLS-0071 for Hypoxic Ischemic Encephalopathy in Newborns

Jul 27, 2023

Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836

Jul 20, 2023

Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations and Topline Results from Phase 2b CODY Study in Gorlin Syndrome

Jul 18, 2023

Engrail Therapeutics Initiates the ENCALM Phase 2 Clinical Trial of ENX-102 in Patients with Generalized Anxiety Disorder

Jul 18, 2023

XyloCor Therapeutics Reports Sustained Results in 12-Month Extension of Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina

Jul 18, 2023

Revolo Biotherapeutics Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis

Jul 18, 2023

OcuTerra Completes Enrollment in Phase 2 DR:EAM Clinical Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathy

Jul 18, 2023

Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder

Jul 12, 2023

Direct Biologics Announces Publication of Significant Survival Benefit with ExoFlo™ in its Phase 2 Randomized Controlled Clinical Trial in the Journal CHEST

Jul 11, 2023

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Positive Biomarker/Clinical Correlations from Phase 2 Biomarker Study at AAIC in Amsterdam

Jun 30, 2023

New Preliminary Findings on Potential Response Indicator of Rakuten Medical's Alluminox Treatment from Phase 2 Window of Opportunity Study at SNMMI 2023

Jun 21, 2023

Boston Pharmaceuticals Announces Positive Phase 2a Results from Monthly and Bi-weekly Dosing with Investigational BOS-580 NASH Program at EASL 2023

Jun 21, 2023

AceLink Therapeutics Receives FDA Clearance to Initiate a Phase 2 Study of AL1211 in Patients with Fabry Disease

Jun 21, 2023

Versanis Bio Announces Completion of Enrollment of the BELIEVE Phase 2b Study in Patients with Obesity

Jun 21, 2023

AISA Pharma Announces Start of Phase 2b Profervia Study for Raynaud's Phenomenon in Systemic Sclerosis (SSc)

Jun 15, 2023

Osivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs

Jun 12, 2023

Trestle Biotherapeutics Wins Prestigious KidneyX Prize

Jun 8, 2023

Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients

Jun 6, 2023

Bold Therapeutics Presents Positive Interim Phase 2 Results for BOLD-100 in Advanced Gastric and Biliary Tract Cancer at ASCO 2023

Jun 6, 2023

BPGbio Announces First Patients Dosed in Phase 2 Trial of AI-Developed BPM 31510 for Glioblastoma Multiforme

Jun 1, 2023

Aravax doses first patient in Phase 2 peanut allergy clinical trials USA - English USA - English

Jun 1, 2023

Aerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO and Expands Management Team as Lead Asset AER-901 (inhaled imatinib) Advances Toward Phase 2 in Pulmonary Hypertension

May 31, 2023

OncoNano Medicine Presents Positive Final Results from Phase 2 Trial of Pegsitacianine in Podium Presentation at 2023 ASCO Annual Meeting

May 30, 2023

AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer

May 30, 2023

DermBiont Announces Positive Data from a Phase 2 Trial Treating Solar Lentigos and Normalizing Pigmentation of the Skin with 0.8% SM-030 Topical Gel

May 25, 2023

AffaMed Therapeutics Announces Partner Allgenesis Reports Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema USA - English APAC - English

May 20, 2023

Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress

May 18, 2023

Boston Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting New Phase 2 Clinical Data from BOS-580 NASH Program at EASL 2023

May 17, 2023

NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn’s Disease

May 16, 2023

AOBiome announces the publication of positive Phase 2b results in The Lancet's eClinicalMedicine for B244 in the treatment of mild-to-moderate atopic dermatitis and moderate-to-severe pruritus

May 15, 2023

Apnimed to Present Positive Phase 2b Results on AD109, an Investigational Oral Treatment for Obstructive Sleep Apnea, at ATS 2023

May 9, 2023

PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

May 8, 2023

Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

May 2, 2023

Amolyt Pharma Announces Phase 3 Clinical Trial of Eneboparatide for the Treatment of Hypoparathyroidism following Positive End of Phase 2 Meeting with FDA

May 2, 2023

Amolyt Pharma annonce l'essai clinique de phase 3 de l'énéboparatide dans le traitement de l'hypoparathyroïdie après des interactions positives de fin de Phase 2 avec la FDA

May 1, 2023

CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA (pembrolizumab) in BCG-Unresponsive NMIBC

Apr 27, 2023

OncoNano Medicine Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

Apr 27, 2023

Nanoscope Therapeutics Announces Presentation of Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa at the ARVO Annual Meeting

Apr 27, 2023

CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

Apr 25, 2023

Prilenia Shares Preliminary Topline Results from Phase 3 PROOF-HD Clinical Trial in Huntington’s Disease and Data from Phase 2 HEALEY ALS Platform Trial of Pridopidine at the 75th American Academy of Neurology (AAN) Annual Meeting

Apr 25, 2023

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

Apr 25, 2023

PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

Apr 19, 2023

Revolo Biotherapeutics Announces Positive Topline Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis

Apr 18, 2023

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study at American Academy of Neurology Conference in Boston

Apr 18, 2023

Bold Therapeutics Presents Jaw-Dropping Interim Phase 2 Clinical Data for BOLD-100 in the Treatment of Advanced Colorectal Cancer at AACR 2023

Apr 18, 2023

Palleon Pharmaceuticals Presents Initial Phase 1 Results from the GLIMMER-01 Clinical Trial for E-602, the First Ever Glyco-Immune Checkpoint Inhibitor

Apr 17, 2023

Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID

Apr 17, 2023

PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID

Apr 17, 2023

Imvax Presents New Data at AACR 2023 Supporting the Mechanism of Action of its Lead Program, IGV-001, for Glioblastoma

Apr 13, 2023

Bold Therapeutics to Present Best-in-Class Phase 2 Metastatic Colorectal Cancer Data at AACR 2023

Apr 11, 2023

MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

Apr 5, 2023

AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)

Apr 3, 2023

Aerami Therapeutics to Host Virtual Investor Day with Leading Experts in Pulmonary Hypertension as AER-901 (Inhaled Imatinib) Advances Toward Phase 2

Mar 31, 2023

AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer’s Disease Phase 2 Study at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2023)

Mar 30, 2023

CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference

Mar 30, 2023

Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa

Mar 28, 2023

Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates

Mar 28, 2023

EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy

Mar 27, 2023

OncoNano Medicine Presents Data from Phase 2 Pegsitacianine Study at Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care

Mar 27, 2023

Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson's Disease

Mar 27, 2023

Imvax Announces First Patient Dosed in Phase 2b Trial of IGV-001 for Glioblastoma

Mar 27, 2023

Revolo Biotherapeutics Announces Completion of Phase 2a Trial of ‘1104 in Allergic Disease

Mar 22, 2023

DermBiont Presents Positive Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel at American Academy of Dermatology Annual Meeting

Mar 14, 2023

Direct Biologics Reports Compelling Results From Phase 2 Trial With ExoFlo™ in Hospitalized Patients With Respiratory Failure or Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19

Mar 14, 2023

AlgoTx Raises €20M to Conduct ATX01’s Phase 2 Program in Peripheral Neuropathic Pain

Mar 9, 2023

Microbion Corporation Initiates Phase 2 Clinical Study Evaluating Topical Pravibismane Treatment of Diabetic Foot Infections

Mar 9, 2023

Palvella Therapeutics Announces Positive Topline Results from Phase 2 Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations, a Serious, Rare Genetic Skin Disease with No FDA-approved Therapies

Mar 7, 2023

MAIA Biotechnology Doses First Patients in Europe in Ongoing Phase 2 Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment

Mar 1, 2023

Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1 Inhibitor for Chronic Gout

Feb 27, 2023

Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease

Feb 27, 2023

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Feb 23, 2023

Prilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study

Feb 23, 2023

Fore Biotherapeutics Announces First Patient Dosed in Global Phase 2 Trial Evaluating FORE8394 in BRAF-Mutated Solid and Brain Tumors

Feb 21, 2023

Palvella Therapeutics Announces Pipeline Update on QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies

Feb 9, 2023

Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer

Feb 7, 2023

Osteal Therapeutics Announces First Subject Enrollment in Second Phase 2 Clinical Trial of VT-X7 Combination Product for Treatment of Periprosthetic Joint Infection

Jan 30, 2023

AmMax Bio Announces First Patients Dosed in Phase 2b Study of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Jan 26, 2023

XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina

Jan 24, 2023

Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin

Jan 23, 2023

OncXerna Therapeutics Announces Final Results and New Xerna™ TME Panel Biomarker Data from a Phase 2 Trial of Bavituximab Plus Pembrolizumab in Patients with Previously Untreated Advanced Hepatocellular Carcinoma

Jan 19, 2023

Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023

Jan 18, 2023

National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma's neflamapimod in dementia with Lewy bodies

Jan 9, 2023

Spiral Therapeutics Completes $8.25M Financing and Initiates Phase 2 Trial in Ménière's Disease

Jan 9, 2023

UNION therapeutics announces positive topline results from the IASOS Phase 2b study of oral orismilast in patients with moderate to severe psoriasis USA - English USA - English

Jan 5, 2023

OnQuality Pharmaceuticals Expands Part 2 of the NOVA-II Phase 2 Clinical Trial to China and India

Jan 5, 2023

Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Allergic Disease

Jan 5, 2023

NorthSea Therapeutics Provides Clinical Update Reflecting Progress Across NASH And Metabolic Disorders Programmes

Jan 5, 2023

Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer

Dec 21, 2022

AEON Biopharma Completes Enrollment in Phase 2 Trial of ABP-450 for Preventive Treatment of Episodic Migraine

Dec 21, 2022

Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study

Dec 21, 2022

Osivax Announces Last Patient Last Visit in Two Phase 2a Clinical Trials with Broad-Spectrum Influenza Vaccine Candidate OVX836

Dec 21, 2022

Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901 (inhaled imatinib), a Critical Milestone Toward the Planned Initiation of a Phase 2 Trial in Pulmonary Arterial Hypertension (PAH) During the First Half of 2023

Dec 20, 2022

MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

Dec 19, 2022

CuraSen Therapeutics Announces Successful Completion of Phase 2 Safety, Tolerability and Proof of Concept Study in Patients with Parkinson’s Disease or Mild Cognitive Impairment (MCI) with CST-103/CST-107 Treatment

Dec 15, 2022

Maze Therapeutics Announces Completion of Phase 1 First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease

Dec 15, 2022

AnHeart Therapeutics Receives FDA Clearance of IND Application to Initiate Global Phase 2 Study of Safusidenib in Glioma

Dec 14, 2022

BioAge Hosting Webcast to Discuss Newly Announced Phase 1b Data Demonstrating BGE-105 Significantly Improves Muscle Atrophy in Older Volunteers on Bed Rest and Detail Phase 2 Plans

Dec 13, 2022

MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe

Dec 12, 2022

Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma

Dec 12, 2022

Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma

Dec 9, 2022

Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction at Ophthalmology Innovation Summit XII

Dec 8, 2022

Context Therapeutics Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Dec 8, 2022

Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)

Dec 7, 2022

Dragonfly Therapeutics lance une étude de phase 2 sur le DF1001 de TriNKET, qui cible les tumeurs HER2, chez des patients atteints de tumeurs solides avancées France - Français España - español USA - English USA - English

Dec 7, 2022

Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022

Dec 6, 2022

Dragonfly Therapeutics Initiates Phase 2 Study of HER2 Targeting TriNKET DF1001 in Patients with Advanced Solid Tumors USA - English USA - English

Dec 6, 2022

Dragonfly Therapeutics Initiates Phase 2 Study of HER2 Targeting TriNKET DF1001 in Patients with Advanced Solid Tumors

Dec 5, 2022

BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Clinical Trial Evaluating Muscle Atrophy in Older Volunteers at Bed Rest

Dec 5, 2022

ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia

Nov 30, 2022

Nimbus Therapeutics Announces Positive Topline Results for Phase 2b Clinical Trial of Allosteric TYK2 Inhibitor in Psoriasis

Nov 29, 2022

Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

Nov 22, 2022

CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors

Nov 18, 2022

AmMax Bio Announces Oral Presentation of Phase 2 Data of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at the 2022 CTOS Annual Meeting

Nov 17, 2022

Escient Pharmaceuticals Initiates Phase 2 PACIFIC Study Evaluating EP547, An Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus

Nov 17, 2022

Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction

Nov 16, 2022

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension

Nov 15, 2022

Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an 'off-the shelf' Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer

Nov 15, 2022

ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers

Nov 15, 2022

Apexigen Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 14, 2022

Sapience Therapeutics Announces Poster Presentation on ST101 Efficacy from Phase 2 Study in Recurrent Glioblastoma (GBM) at Society for Neuro-Oncology (SNO) Annual Meeting

Nov 14, 2022

Apexigen Announces Positive Interim Results from Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Doxorubicin in Patients with Liposarcoma

Nov 11, 2022

NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer

Nov 10, 2022

Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic Gout at American College of Rheumatology Annual Meeting, Nov. 10 – 14, in Philadelphia, PA

Nov 10, 2022

CG Oncology Presents New Phase 2 Data With CG0070 in Combination With KEYTRUDA (pembrolizumab) in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin

Nov 9, 2022

Revolo Biotherapeutics Announces That the Last Patient in its Phase 2a Trial of ‘1104 in Eosinophilic Esophagitis has Completed the Study

Nov 8, 2022

OnQuality Pharmaceuticals Announces the Enrollment of the First Patient in Part 2 of the NOVA-II Phase 2 Clinical Trial

Nov 8, 2022

ACELYRIN, INC. Announces Phase 2 Data for Izokibep in Psoriatic Arthritis That Demonstrate Broad Clinical Efficacy - including in Difficult-to-Treat Manifestations - Driving Meaningful Benefits for Patients Such as Improved Pain, Sleep, and Physical Function

Nov 4, 2022

Rivus Pharmaceuticals to Present Results from a Phase 2a Trial Evaluating its Controlled Metabolic Accelerator, HU6, at the American Association for the Study of Liver Diseases (AASLD)2022 Meeting

Nov 4, 2022

Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection

Nov 3, 2022

Laurent Pharmaceuticals Presents Results from Phase 2 Clinical Study of LAU-7b in Cystic Fibrosis at the NACFC 2022

Nov 3, 2022

Sagimet Biosciences Announces Positive Interim Phase 2b Clinical Trial Data with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Moderate-to-Severe Non-alcoholic Steatohepatitis (NASH) Patients

Oct 31, 2022

Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)

Oct 27, 2022

Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300

Oct 27, 2022

Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity

Oct 27, 2022

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

Oct 24, 2022

CG Oncology to Present New Phase 2 Data with CG0070 in Combination with KEYTRUDA (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin at SITC 2022

Oct 21, 2022

Anokion Announces Presentation of Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease at the 19th International Celiac Disease Symposium

Oct 18, 2022

Anokion Announces $35 Million Equity Investment from Pfizer

Oct 18, 2022

Istari Oncology Announces Presentation of Clinical Responses from LUMINOS- 102, an ongoing Phase 2 Trial of Lerapolturev in anti-PD-1 Refractory Metastatic Melanoma at the Society for Melanoma Research (SMR) 2022 Congress

Oct 18, 2022

LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia

Oct 17, 2022

Inversago Pharma Raises $95 million CAD in Series C Financing

Oct 17, 2022

Apollo Provides Update on Phase 2 Drill Program at Calico Silver Project

Oct 12, 2022

Amolyt Pharma Announces Positive Safety and Efficacy Results from Second Patient Cohort in its Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism

Oct 12, 2022

Amolyt Pharma présentera prochainement les données complètes de son étude de phase 2a de l’AZP-3601 lors de deux conférences

Oct 12, 2022

Amolyt Pharma to Present Full Phase 2a Data on AZP-3601 at Upcoming Conferences

Oct 5, 2022

NewAmsterdam Pharma Announces Initiation of Phase 2 Dose-Finding Study Evaluating Obicetrapib in Japanese Patients

Oct 4, 2022

AIVITA Biomedical Announces Publication Detailing 50% Enhanced Survival in Phase 2 GBM Study

Oct 4, 2022

Sapience Therapeutics Awarded SBIR Phase 2 Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST101 in Breast Cancer

Sep 29, 2022

Trefoil Therapeutics Announces Positive TTHX1114 Phase 2 Study Data Showing Corneal Regeneration and Vision Recovery Following Descemet Stripping Only (DSO) Surgery

Sep 29, 2022

Entos Pharmaceuticals Passes Significant Enrollment Milestone in Phase 2 Clinical Trial of its COVID-19 DNA Vaccine

Sep 29, 2022

OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis

Sep 28, 2022

Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction

Sep 28, 2022

Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial to Evaluate EVO101 in Atopic Dermatitis

Sep 26, 2022

Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer

Sep 23, 2022

AEON Biopharma Reports Positive Topline Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia

Sep 21, 2022

EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications

Sep 20, 2022

Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease

Sep 20, 2022

Additional Study Augments the Results of AOBiome's Successful 547 Patient Phase 2b Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis and Moderate-to-Severe Pruritus using its B244 investigational drug

Sep 19, 2022

Zucara Therapeutics' Positive Proof-of-Concept Data Secures Continued Funding Ahead of Planned Phase 2 Clinical Trial of ZT-01

Sep 15, 2022

Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease

Sep 14, 2022

Karolinska Development’s portfolio company Umecrine Cognition secures funding ahead of Phase 2 study of golexanolone in primary biliary cholangitis

Sep 14, 2022

OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022

Sep 13, 2022

Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Sep 13, 2022

Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation

Sep 12, 2022

Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)

Sep 12, 2022

Nimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology

Sep 12, 2022

Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Eosinophilic Esophagitis

Sep 12, 2022

Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study of AZP-3601 in Patients with Hypoparathyroidism at the American Society for Bone and Mineral Research 2022 Annual Meeting

Sep 12, 2022

AmMax Bio Announces Presentation of Phase 2 PK/PD Data of ABM-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at ESMO Congress 2022

Sep 12, 2022

OncXerna Therapeutics Announces New Xerna™ TME Panel Biomarker Data from Retrospective Analysis of Results from a Randomized Phase 2 Trial Evaluating Anti-PD-1 Maintenance Therapy in Esophagogastric Adenocarcinoma at the ESMO Congress 2022

Sep 10, 2022

Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022

Sep 8, 2022

YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine

Sep 8, 2022

Autobahn Therapeutics Announces Successful Financing to Support Strategic Advancement of ABX-002 for Treatment Resistant Depression

Sep 8, 2022

Cardior Announces CE Marking of CardiorHealth miR-132 PCR Kit Used in Ongoing HF-REVERT Phase 2 Clinical Study

Sep 8, 2022

OncXerna Therapeutics Doses First Patient in Phase 2 Trial Evaluating Navicixizumab Alone or in Combination with Chemotherapy in Patients with Select Advanced Solid Tumors

Sep 7, 2022

InxMed Announces First Patient Dosed in Phase 2 Pivotal Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer

Sep 7, 2022

CuraSen Therapeutics Announces First Patients Treated with Novel Combination Therapy (CST-2032/CST-107) in Phase 2a Study of Mild Cognitive Impairment (MCI) or Mild Dementia Due to Parkinson’s or Alzheimer’s Disease

Sep 7, 2022

Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 2 Study of D-4517.2 for the Treatment of Wet AMD and DME 

Sep 5, 2022

Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022

Sep 1, 2022

Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS)

Sep 1, 2022

Amolyt Pharma Announces Two Presentations, Including Phase 2a Data for AZP-3601 in Patients with Hypoparathyroidism, at the American Society for Bone and Mineral Research 2022 Annual Meeting

Aug 30, 2022

Aristea Therapeutics Announces Dosing of First Patient in Phase 2a Trial of RIST4721 in Hidradenitis Suppurativa

Aug 30, 2022

HighTide Therapeutics Announces Early Completion of Enrollment in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus

Aug 29, 2022

AIVITA Biomedical Announces Publication of Phase 1 and Phase 2 Trial Results of its COVID-19 Vaccine Candidate

Aug 25, 2022

Sermonix Pharmaceuticals Announces Top-Line Data From ELAINE 1 Phase 2 Study of Lasofoxifene Versus Fulvestrant Is Accepted for a Late-Breaking Oral Presentation at ESMO Congress 2022

Aug 22, 2022

Imbria Pharmaceuticals to Present Phase 2a Data from the Ninerafaxstat Program at the European Society of Cardiology Congress 2022

Aug 10, 2022

Disc Medicine Initiates BEACON, a Phase 2 Clinical Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)

Aug 10, 2022

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

Aug 8, 2022

Sapience Therapeutics Announces Surgical Sub-Study of Ongoing Phase 1-2 Trial of ST101 in Recurrent and Newly Diagnosed GBM Patients

Aug 4, 2022

Noema Pharma Announces Recruitment of First Patient in Orpheus Phase 2b Study of PDE10A Inhibitor gemlapodect in Adults with Childhood Onset Fluency Disorder

Aug 4, 2022

UNION therapeutics announces enrollment of the first patient in ADESOS Phase 2b study of orismilast MR tablet in patients with atopic dermatitis

Aug 2, 2022

OcuTerra Therapeutics Announces First Patient Dosed in OTT166 Phase 2 DR:EAM Clinical Trial for Diabetic Retinopathy

Aug 2, 2022

Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China

Aug 1, 2022

Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company

Jul 26, 2022

Alzheon to Present Industry-Leading Phase 2 Biomarker and Clinical Data with ALZ-801 (Valiltramiprosate) Oral Tablet at 2022 Alzheimer’s Association International Conference

Jul 25, 2022

Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Jul 25, 2022

Ashvattha Therapeutics Announces Publication of Data in Science Translational Medicine from Phase 2a Clinical Trial for OP-101 in Severe COVID-19 Showing Significant Reduction in Inflammatory and Neuroinflammatory Markers and Improved Clinical Outcomes

Jul 20, 2022

Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNA-Based Lead Candidate CDR132L in Heart Failure Patients Post-Myocardial Infarction

Jul 20, 2022

Versanis Bio Announces Leadership and Board Appointments as Company Prepares to Initiate Phase 2b Study with Novel Approach to Obesity

Jul 19, 2022

Cardurion Pharmaceuticals Announces Dosing of Patients in CARDINAL-HF, a Phase 2 Clinical Trial of its PDE9 inhibitor in Heart Failure

Jul 18, 2022

MAIA Biotechnology Doses First Patient With THIO in Phase 2 Trial (THIO-101) for Non-Small Cell Lung Cancer

Jul 7, 2022

Goldfinch Bio Announces Publication in Science Advances on the Validation of Human Derived Organoids as a Predictable and Translatable Preclinical Model in Kidney Disease for the Evaluation of Therapeutic Drug Candidates

Jun 30, 2022

Aristea Therapeutics Announces Dosing of First Patient in Open-Label Extension for Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis

Jun 28, 2022

XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease

Jun 28, 2022

NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

Jun 28, 2022

Apnimed Granted FDA Fast Track Designation for AD109, a Novel First-in-Class Oral Pharmacologic Combination for the Treatment of Obstructive Sleep Apnea (OSA)

Jun 28, 2022

BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC)

Jun 27, 2022

Noema Pharma Announces FDA Investigational New Drug (IND) Authorization for Orpheus Phase 2b Study of PDE10A Inhibitor Gemlapodect (NOE-105) in Childhood Onset Fluency Disorder

Jun 27, 2022

Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer

Jun 25, 2022

Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study

Jun 23, 2022

DermBiont Announces Positive Phase 2 Clinical Trial Data Treating Seborrheic Keratosis with SM-020, the First and Only Targeted Topical Treatment for these Common Benign Tumors

Jun 21, 2022

Rakuten Medical Taiwan Announces Commencing a Phase 2 Clinical Trial for Head and Neck Squamous Cell Carcinoma Photoimmunotherapy based on the Alluminox™ platform at 5 Leading Medical Centers and the Enrollment of First Patient

Jun 21, 2022

Tranquis Therapeutics Granted FDA Orphan Drug Designation for TQS-168 for the Treatment of Amyotrophic Lateral Sclerosis

Jun 15, 2022

Renibus Therapeutics Announces Positive Interim Data from RBT-1 Phase 2 Trial

Jun 14, 2022

HUYABIO INTERNATIONAL ANNOUNCES INITIATION OF HBI-3000 PHASE 2 TRIAL

Jun 9, 2022

Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs

Jun 8, 2022

Sermonix Pharmaceuticals’ Phase 2 Lasofoxifene Trial Poster Receives a GRASP Advocate Choice Award, Selected for Post-ASCO Patient Advocate Investigator Discussions

Jun 7, 2022

Engrail Therapeutics Announces Positive Results of ENX-101 Phase 1b Clinical Study and Prepares for Initiation of ENACT Phase 2 Trial in Focal Epilepsy

Jun 7, 2022

AUM Biosciences Announces FDA IND Authorization for Global Phase 2 Trial of Selection Translation Inhibitor AUM001 in Colorectal Cancer

Jun 6, 2022

Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with Chemotherapy

Jun 6, 2022

NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals

Jun 6, 2022

Elevar Therapeutics Shares Results of Phase 2 Rivoceranib Trial in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma

Jun 4, 2022

CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Jun 3, 2022

ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress

Jun 3, 2022

OncXerna Therapeutics Announces Upcoming ASCO Poster Featuring Data Showing the Phase 2 Glioblastoma Trial of Bavituximab with Chemoradiation and Adjuvant Temozolomide Met its Primary Endpoint

Jun 2, 2022

Sapience Therapeutics Announces Expansion of Phase 2 Study Arm with ST101 in Patients with Recurrent Glioblastoma (GBM) Based on Confirmed Partial Response (PR)

Jun 2, 2022

Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168

Jun 1, 2022

Dyve Biosciences Announces Phase 2 TARGETS Study of DYV702 for Pain Associated with Acute Gout Flares Showcased in Podium Presentation at 2022 EULAR Congress

Jun 1, 2022

Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism

Jun 1, 2022

FDA Grants AlgoTx IND Clearance for Phase 2 Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy

May 31, 2022

Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)

May 26, 2022

Elevar Therapeutics Announces Rivoceranib Demonstrated Clinical Effectiveness in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma in a Phase 2 Trial

May 24, 2022

PureTech Founded Entity Vedanta Biosciences Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting

May 23, 2022

Anokion Announces Positive Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease Presented in a Plenary Session at DDW 2022

May 19, 2022

NewAmsterdam Pharma to Present at Upcoming Medical Conferences New Post-Hoc Analyses from Phase 2 ROSE Trial of Obicetrapib in Patients with Dyslipidemia

May 19, 2022

MAIA Biotechnology, Inc. Establishes Wholly Owned Subsidiaries in Romania and Australia to Support Global Development of THIO

May 19, 2022

Karolinska Development's portfolio company Umecrine Cognition submits a Clinical Trial Application to initiate a phase 2 clinical trial with golexanolone

May 18, 2022

Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101

May 18, 2022

Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation

May 18, 2022

XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT

May 17, 2022

HUYABIO INTERNATIONAL ANNOUNCES COMPLETION OF HBI-3000 PHASE 1 TRIAL AND FDA APPROVAL TO PROCEED WITH DOSE ESCALATION IN PHASE 2

May 16, 2022

CG Oncology Presents Additional Phase 2 Data with CG0070 in Combination with KEYTRUDA (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

May 10, 2022

Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

May 6, 2022

Sen-Jam Pharmaceutical Opens Enrollment for Patients in Their COVID Therapy Phase 2 Clinical Trial in Nepal and Engages With Strategic Investor for Worldwide Distribution

May 4, 2022

AriBio Co., Ltd. Announces the Successful Completion of Their End of Phase 2 Meeting With the USFDA

May 3, 2022

ACELYRIN, INC., Affibody AB, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis

Apr 28, 2022

HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer

Apr 28, 2022

HighTide Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus

Apr 23, 2022

Orasis Pharmaceuticals Announces Phase 2b Trial Efficacy and Safety Results of Novel Presbyopia Eye Drop Candidate, CSF-1, at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 21, 2022

Osivax Announces Publication of Phase 2a Trial Results for Influenza Vaccine Candidate OVX836 in Frontiers in Immunology

Apr 19, 2022

Neuraly Announces Completion of Enrollment in Phase 2 Clinical Trial of NLY01 in Patients with Parkinson’s Disease

Apr 19, 2022

BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications

Apr 13, 2022

Phosplatin Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of PT-112 for Thymoma and Thymic Carcinoma in Collaboration with National Cancer Institute

Apr 13, 2022

Highlight Therapeutics announces follow-up results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR

Apr 13, 2022

PureTech Founded Entity Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host and Microbe and Highlights Planned Presentations of Phase 2 VE303 Results

Apr 13, 2022

CG Oncology Presents Interim Phase 2 Data with CG0070 in Combination with KEYTRUDA (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Apr 13, 2022

Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host and Microbe and Highlights Planned Presentations of Phase 2 VE303 Results

Apr 12, 2022

Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with Metastatic Melanoma Presented at the AACR Annual Meeting 2022

Apr 12, 2022

Orasis Pharmaceuticals to Present New Data on Novel Presbyopia Candidate at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting USA - English USA - English

Apr 11, 2022

AEON Biopharma Completes Enrollment in Phase 2 Clinical Study of ABP-450 in Cervical Dystonia

Apr 7, 2022

Apexigen Announces That New Data From Phase 2 Trial Evaluating its CD40 Antibody Sotigalimab in Combination With Pembrolizumab in Patients With Metastatic Melanoma Will Be Presented at the AACR Annual Meeting 2022

Apr 6, 2022

Linnaeus Therapeutics Awarded $4,000,000 SBIR Phase 2 Bridge Award by the National Cancer Institute to Advance LNS8801 for the Treatment of Cutaneous and Uveal Melanoma

Apr 5, 2022

NewAmsterdam Pharma Doses First Patient in Phase 2 Trial of Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy

Apr 5, 2022

Lakewood-Amedex Enrolls First Patient in Phase 2 Clinical Trial for Patients with Chronic Diabetic Foot Ulcers (cDFU)

Mar 31, 2022

Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism

Mar 30, 2022

Concentric Analgesics Announces Positive Results from Pilot Phase 2 Clinical Trial of Vocacapsaicin in Open Laparotomy for Repair of Abdominal Ventral Hernia

Mar 28, 2022

Aristea Therapeutics Announces Dosing of First Patient in Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis

Mar 24, 2022

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint

Mar 22, 2022

Goldfinch Bio to Host Virtual Event on Unmet Need in Focal Segmental Glomerulosclerosis (FSGS) and GFB-887 as a Novel Kidney Precision Medicine Candidate

Mar 21, 2022

Nature Paper: BioAge’s Oral Drug Targeting the Aging Immune System Prevents Death From COVID-19 in Aged Mice

Mar 21, 2022

Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout

Mar 15, 2022

MAIA Biotechnology, Inc. Announces HREC Approval in Australia for its THIO-101 Phase 2 Trial for NSCLC

Mar 10, 2022

CalciMedica Announces Publication of Peer-Reviewed Paper in The Journal of Physiology; Study Supports Development of CRAC Channel Inhibitors for Acute Pancreatitis

Mar 9, 2022

Apnimed Study APC-004 Phase 2 Data to be Presented at World Sleep 2022

Mar 8, 2022

Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease at AD/PD and NDDS Scientific Conferences

Mar 4, 2022

Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy

Mar 2, 2022

AmMax Bio Announces Positive Phase 2 Results Demonstrating Proof-of-Concept for the Novel Local Delivery of AMB-05X in Patients with Tenosynovial Giant Cell Tumor (TGCT)

Mar 2, 2022

Xalud Therapeutics Doses First Patient in Phase 2a Trial of XT-150 for the Treatment of Facet Joint Osteoarthritis Pain

Mar 1, 2022

Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer

Mar 1, 2022

Bold Therapeutics Successfully Completes Phase 1b Trial and Advances into Global Phase 2 Trial of BOLD-100 in the Treatment of Advanced GI Cancers

Mar 1, 2022

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion

Feb 28, 2022

Goldfinch Bio Announces Positive Preliminary Data from Phase 2 Clinical Trial Evaluating GFB-887 as a Precision Medicine for Patients with Focal Segmental Glomerular Sclerosis (FSGS)

Feb 28, 2022

Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)

Feb 22, 2022

Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia

Feb 22, 2022

AOBiome Therapeutics' topical biotherapeutic B244 demonstrated positive Phase 2b results from its 547 patient trial for both Pruritus (Itch) and Appearance in its 547 patient Phase 2b trial of Atopic Dermatitis (Eczema)

Feb 18, 2022

Revalesio Announces the Design of RESCUE, a Phase 2 Trial of RNS60 in Acute Ischemic Stroke, and the Presentation of Preclinical Data at the International Stroke Conference 2022

Feb 16, 2022

Memo Therapeutics AG Closes Series B Financing at CHF37 Million Following Oversubscribed CHF23 Million Extension

Feb 15, 2022

Rakuten Medical and Shimadzu Enroll First Patient in the U.S. Clinical Trial of Photoimmunotherapy

Feb 15, 2022

Laurent Pharmaceuticals Starts Phase 3 Study With Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients

Feb 14, 2022

Noema Pharma Announces FDA Investigational New Drug Authorization for Phase 2b LibraTN Study of mGluR5 Inhibitor NOE-101 in Trigeminal Neuralgia

Feb 14, 2022

OnQuality Pharmaceuticals to Present NOVA-II Phase 2 Trial Update and Oncologist Survey Demonstrating Oncodermatology Unmet Need at ASCO GU

Feb 9, 2022

Rivus Pharmaceuticals Announces Positive Data from Phase 2a Clinical Trial of Lead Candidate HU6, Demonstrating Fat Reduction and Weight Loss in High BMI Participants

Feb 8, 2022

Alzheon Reports Industry-Leading Disease Modifying Effects from Phase 2 Biomarker Trial of Oral Tablet ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease

Feb 7, 2022

Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision

Feb 7, 2022

NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers

Feb 4, 2022

Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom

Feb 2, 2022

Acticor Biotech: Results of the Phase 2 GARDEN Study in COVID-19-Related Acute Respiratory Distress Syndrome

Jan 24, 2022

Goldfinch Bio Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer

Jan 24, 2022

SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19

Jan 18, 2022

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613 (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Jan 17, 2022

Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity

Jan 13, 2022

Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study

Jan 6, 2022

Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101

Jan 6, 2022

Biosight Reports Final Primary Endpoint Data from Phase 2b Study of Aspacytarabine (BST-236) for First-Line Acute Myeloid Leukemia Therapy

Jan 6, 2022

Nimbus Therapeutics Announces Expansion of Oral Allosteric TYK2 Inhibitor Program and Provides Additional Business Updates

Jan 6, 2022

Anokion Announces Progress Across Pipeline of Novel Autoimmune Programs

Jan 5, 2022

NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma

Jan 4, 2022

OnQuality Pharmaceuticals Reports Topline Data from Phase 2 Trial of Treatment for Cancer Therapy Induced Skin Toxicity that Met Expectations

Jan 4, 2022

UNION therapeutics announces enrollment of first patient in the IASOS Phase 2b study of oral orismilast in psoriasis patients

Jan 4, 2022

Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA

Jan 4, 2022

OrphoMed, Inc. Announces Positive Phase 2 Results for ORP-101 100 mg Once-Daily Dose in IBS-D Patients

Jan 3, 2022

Stuart Therapeutics, Inc. Announces Successful Phase 2 Clinical Trial Results of its Novel Dry Eye Candidate ST-100

Dec 16, 2021

Apnimed Announces Dosing of First Patient in Phase 2 MARIPOSA Confirmatory Trial of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea (OSA)

Dec 15, 2021

Laurent Pharmaceuticals Extends COVID-19 Phase 2 Study with Oral Antiviral LAU-7b that has Showed 100% Reduction in the Risk of Progression onto Mechanical Ventilation and Death

Dec 14, 2021

HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA (pembrolizumab) in Patients with Metastatic Breast Cancer

Dec 14, 2021

ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis

Dec 14, 2021

Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection

Dec 13, 2021

Rafael Pharmaceuticals Announces Published Data on CPI-613 (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 13, 2021

Tessa Therapeutics Announces Positive Data from Phase 2 Trial of Autologous CD30-CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma at 2021 ASH Annual Meeting

Dec 9, 2021

CinCor Pharma, Inc., Doses First Patient in HALO, a Phase 2 Clinical Trial Evaluating CIN-107, a Selective Aldosterone Synthase Inhibitor, in Patients with Uncontrolled Hypertension and High Plasma Aldosterone

Dec 9, 2021

Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients

Dec 8, 2021

Shasqi Awarded a Second NCI Grant of $1.9M to Accelerate the Development of SQ3370

Dec 7, 2021

HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium

Dec 6, 2021

Goldfinch Bio Strengthens Leadership Team with Appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer

Dec 2, 2021

ZZ Biotech Announces First Patients Dosed in Phase 2 Clinical Trial of 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Dec 1, 2021

SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus

Nov 30, 2021

Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia

Nov 22, 2021

Concentric Analgesics Announces Poster Presentation of Positive Vocacapsaicin Data from Total Knee Arthroplasty Phase 2 Study at the 2021 American Academy of Hip and Knee Surgeons Annual Meeting

Nov 18, 2021

Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 2 Study of AP-101 for the Treatment of ALS

Nov 16, 2021

ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases

Nov 16, 2021

AOBiome Achieves Landmark Recruitment Goal in Largest Clinical Trial Ever Powered by a Live Topical Biotherapeutic

Nov 15, 2021

Phosplatin Therapeutics Collaborates with the National Cancer Institute For Phase 2 Proof of Concept Study of PT-112 in Thymoma and Thymic Carcinoma

Nov 15, 2021

MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma

Nov 15, 2021

Versantis to Present Positive Phase 1b Data at AASLD for VS-01 in Patients with Decompensated Cirrhosis

Nov 13, 2021

NewAmsterdam Pharma Presents Full Results from Phase 2 ROSE Study of Obicetrapib in Patients with Dyslipidemia

Nov 13, 2021

CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Nov 12, 2021

New Data from Sagimet's Phase 2 FASCINATE-1 Clinical Trial Demonstrate TVB-2640's Positive Effect Across Patients with NASH in the U.S. and China

Nov 12, 2021

Apexigen Announces New Phase 2 Clinical Data on CD40 Antibody Sotigalimab at the SITC 2021 Annual Meeting

Nov 12, 2021

Biosight Announces Initiation of Phase 2 Clinical Trial of Aspacytarabine for MDS and AML

Nov 10, 2021

EIP Pharma announces that final results of the AscenD-LB phase 2 clinical study demonstrates neflamapimod has disease-modifying potential in dementia with Lewy Bodies

Nov 9, 2021

OcuTerra Raises $35 Million Series B Financing

Nov 9, 2021

Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Nov 9, 2021

Apexigen To Host Key Opinion Leader Webinar on Sotigalimab in Post-Anti-PD-(L)1 Melanoma

Nov 8, 2021

NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in Combination with PD-L1 Checkpoint Inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Nov 8, 2021

Goldfinch Bio Showcases Biology, Genetic and Clinical Programs at ASN Kidney Week Demonstrating Leadership in Precision Medicines for Kidney Diseases

Nov 8, 2021

NewAmsterdam Pharma Announces ROSE Phase 2 Trial Results Accepted for Featured Science Presentation at 2021 AHA Scientific Sessions

Nov 4, 2021

EIP Pharma Announces New Data Presentations from Phase 2 Treatment Trial in Dementia with Lewy Bodies at Upcoming Scientific Conference and New Board Appointment

Nov 4, 2021

AriBio Co., Ltd. Announces Topline Results from Phase 2 Study of AR1001 in Mild to Moderate Alzheimer’s Patients

Nov 3, 2021

Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV

Nov 2, 2021

HUYABIO INTERNATIONAL ANNOUNCES INITIATION OF PHASE 2 ATRIAL FIBRILLATION TRIAL

Nov 1, 2021

Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801 Oral Tablet at Clinical Trials in Alzheimer’s Disease (CTAD) Conference

Nov 1, 2021

Rivus Pharmaceuticals Announces Positive Results from Phase 1 Trial of Lead Candidate HU6, Demonstrating Safety, Efficacy in Key Targets for Multiple Cardio-Metabolic Diseases

Nov 1, 2021

Tarveda Therapeutics Announces Data from Phase 2 Trial of PEN-221 to Be Presented at NANETS 2021 Multidisciplinary NET Virtual Symposium

Oct 28, 2021

Revolo Biotherapeutics Activates Clinical Sites and Opens Enrollment in a Phase 2 Clinical Trial of ‘1104 in Eosinophilic Esophagitis

Oct 25, 2021

AnHeart Therapeutics Announces First Patient Dosed in Global Phase 2 TRUST-II Study for Taletrectinib in ROS1 Fusion-Positive Lung Cancer

Oct 21, 2021

Revolo Biotherapeutics Activates Clinical Trial and Commences Enrollment in Phase 2 Clinical Study of ‘1104 in Allergic Disease in the UK

Oct 20, 2021

AmMax Bio Announces Positive Interim Phase 2 Results of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Oct 19, 2021

Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting

Oct 14, 2021

UNION therapeutics announces enrollment of first patient in the OSIRIS Phase 2a study of oral orismilast for the treatment of mild to severe hidradenitis suppurativa

Oct 14, 2021

Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study for ICU-Acquired Weakness

Oct 13, 2021

Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment

Oct 13, 2021

Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Investigational Treatment for the Disease

Oct 12, 2021

CG Oncology to Present Two Programs at The Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Oct 11, 2021

Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting

Oct 6, 2021

Lumen Bioscience Awarded Federal Funding to Advance Covid-19 Antibody Cocktail through Phase 2 Clinical Evaluation

Oct 4, 2021

Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD's The Liver Meeting 2021

Oct 4, 2021

Boston Pharmaceuticals Doses First Patient in Phase 2a Clinical Trial of BOS-580 for NASH

Oct 4, 2021

Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society

Oct 1, 2021

Apexigen Announces Presentation of Phase 2 Clinical Data on CD40 Antibody Sotigalimab at the SITC 2021 Annual Meeting

Sep 30, 2021

Laurent Pharmaceuticals Announces Topline Results from its Phase 2 RESOLUTION Clinical Trial of LAU-7b for the Treatment of COVID-19

Sep 28, 2021

UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions

Sep 26, 2021

Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting

Sep 24, 2021

SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19

Sep 22, 2021

Endeavor BioMedicines Doses First Patient in Phase 2 Clinical Trial of Taladegib (ENV-101) for Idiopathic Pulmonary Fibrosis; Appoints Chief Medical Officer

Sep 21, 2021

HighTide Therapeutics’ HTD1801 Demonstrates Reduced Liver Fat, Improved Glycemic Control and Other Health Measures in Diabetic NASH Patients

Sep 21, 2021

Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study

Sep 21, 2021

Rhizen Pharmaceuticals AG Announces First Patient Dosed in a Phase 2 Study of RP7214 in Covid-19 Patients

Sep 16, 2021

OncXerna Therapeutics Announces New Phase 2 and Biomarker Data in Gastric Cancer from Bavituximab Program at the ESMO Congress 2021

Sep 15, 2021

SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza

Sep 14, 2021

CalciMedica Reports Topline Data from the AuxoraTM CARDEA Phase 2 COVID-19 Pneumonia Clinical Trial

Sep 14, 2021

Nimbus Therapeutics Announces First Patient Dosed in Phase 2b Study of Oral Allosteric TYK2 Inhibitor in Patients with Moderate to Severe Psoriasis

Sep 13, 2021

AIVITA Biomedical Announces 96% Immune Response Against SARS-CoV-2 in Phase 2 Clinical Trial of a Personalized Vaccine

Sep 13, 2021

Alzheon Appoints Adem Albayrak as Head of Operations and Earvin Liang, PhD, as Vice President of Clinical Development

Sep 8, 2021

Stuart Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase 2 Clinical Trial for Dry Eye Disease

Sep 8, 2021

Nanoscope Therapeutics Announces Presentation of Positive Results from Optogenetic Gene Therapy for Retinal Degenerative Diseases at the EURETINA 2021 Virtual Conference

Sep 7, 2021

Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function

Sep 2, 2021

Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases

Sep 2, 2021

Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals

Aug 25, 2021

BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors

Aug 25, 2021

Rafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613 (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Aug 18, 2021

HistoIndex's Stain-free AI-based Digital Pathology Incorporated as Secondary and Exploratory Efficacy Endpoints in Sagimet's NASH FASCINATE-2 Phase 2b Clinical Trial

Aug 16, 2021

Biosight Announces Initiation of Investigator Sponsored Phase 2 Clinical Trial of Aspacytarabine for Relapsed/Refractory AML and MDS with the Groupe Francophone des Myélodysplasies

Aug 16, 2021

Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis

Aug 16, 2021

Sermonix Pharmaceuticals Completes Enrollment of Phase 2 ELAINE 1 Randomized Clinical Trial Assessing Efficacy of Oral Lasofoxifene Versus Intramuscular Fulvestrant

Aug 12, 2021

Sen-Jam Pharmaceutical Partners With Duke-NUS Medical School for a Phase 2 Trial for a New COVID 19 Treatment

Aug 11, 2021

Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)

Aug 11, 2021

Cali Biosciences Initiates Phase 2b Study of Long-Acting Ropivacaine for Non-Opioid Treatment of Post-Operative Pain

Aug 10, 2021

Goldfinch Bio Announces Initiation of Open-Label Extension Study for Patients with Focal Segmental Glomerular Sclerosis (FSGS) Enrolled in Phase 2 Clinical Trial of GFB-887

Aug 5, 2021

Noema Pharma Initiates Phase 2a Allevia Study of PDE10A Inhibitor NOE-105 in Tourette Syndrome

Aug 4, 2021

eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer

Aug 3, 2021

Lutris Pharma Doses First U.S. Patients in Phase 2 Trial of LUT014 -- a Topical Gel for the Reduction of Dose-Limiting Acneiform Lesions -- in Metastatic Colorectal Cancer Patients Treated with EGFR Inhibitor Therapy USA - English USA - English USA - English

Aug 2, 2021

FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus

Jul 30, 2021

Revolo Biotherapeutics Announces Clinical Trial Authorization to Initiate Phase 2 Trial of ‘1104 in Allergic Disease in the UK

Jul 30, 2021

ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients

Jul 28, 2021

NewAmsterdam Pharma Reports Positive Results from Phase 2 Study of Oral Obicetrapib Demonstrating Over 50% LDL-Lowering as an Adjunct to High-Intensity Statins

Jul 28, 2021

ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks

Jul 27, 2021

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

Jul 26, 2021

Published Results from Sagimet's FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640's Ability to Significantly Reduce Excess Liver Fat

Jul 24, 2021

Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease

Jul 22, 2021

HemoShear Therapeutics Announces First Two Patients Dosed in Phase 2 Study of Oral Small Molecule HST5040 for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

Jul 21, 2021

Vedanta Biosciences Completes $68 Million Series D Financing

Jul 21, 2021

PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing

Jul 19, 2021

Anthos Therapeutics' novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine

Jul 19, 2021

Imbria Pharmaceuticals Announces Initiation of Enrollment in IMPROVE-HCM, a Phase 2 Study Investigating the Safety, Tolerability, and Efficacy of IMB-1018972 (IMB-101) in Patients With Non-Obstructive Hypertrophic Cardiomyopathy

Jul 19, 2021

Nanoscope Therapeutics Announces First Patient Dosed in Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa

Jul 19, 2021

Allegro Ophthalmics to Present the Results of ALG-1007 Ex-U.S. Phase 2 Clinical Trial for Dry Eye Disease at the 2021 ASCRS ASOA Annual Meeting

Jul 19, 2021

Anthos Therapeutics' novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine USA - English France - Français Deutschland - Deutsch USA - slovenčina USA - Pусский Brazil - Português USA - Deutsch

Jul 14, 2021

Sirnaomics Doses First Patient in Phase 2 Study of STP705 for Keloid Scar Prevention

Jul 13, 2021

Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress

Jul 13, 2021

Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs

Jul 12, 2021

Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae

Jul 2, 2021

SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza

Jun 30, 2021

Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)

Jun 30, 2021

Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancer

Jun 30, 2021

PureTech Founded Entity Vedanta Biosciences Announces New Data from Phase 1 Study of VE202 for the Treatment of Inflammatory Bowel Disease

Jun 30, 2021

Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2a Study of EMB-001 in Smoking Cessation

Jun 29, 2021

Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)

Jun 28, 2021

Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib

Jun 23, 2021

Alzheon Completes Patient Enrollment in Phase 2 Biomarker Trial of ALZ-801 Oral Tablet in APOE4 Carriers with Alzheimer’s Disease

Jun 23, 2021

Revolo Biotherapeutics Announces US FDA Approval of IND Application for Phase 2 Trial of ‘1104 in Eosinophilic Esophagitis

Jun 23, 2021

Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa

Jun 22, 2021

Imbria Pharmaceuticals Announces Enrolment of the First 10 Patients in IMPROVE-DiCE, an Exploratory Phase 2 Study Investigating the impact of IMB-1018972 on Cardiac Energetics, Metabolism and Function in Patients with Type 2 Diabetes

Jun 21, 2021

HighTide Therapeutics Announces the Presentation of Topline Results of Phase 2 Study of HTD1801 in PSC Patients at the International Liver Congress 2021

Jun 16, 2021

ReViral Announces Positive Recommendation by the Data Safety Monitoring Committee to Continue the Phase 2 Clinical Study of Sisunatovir for Treatment of Respiratory Syncytial Virus Infections in Hospitalized Infants

Jun 16, 2021

Starton Therapeutics Phase 2 TROPIC-I Clinical Study will be First to Use Total Control Primary Endpoint in Superiority Study

Jun 16, 2021

Apexigen and the Nordic Society of Gynaecological Oncology – Clinical Trial Unit Announce Collaborative Phase 2 Study of Sotigalimab (APX005M) in Combination Therapy for Ovarian Cancer

Jun 16, 2021

Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma

Jun 15, 2021

Ashvattha Therapeutics Announces Positive Interim Data from Ongoing Phase 2 PRANA Clinical Study of OP-101 in Severe COVID-19 Patients

Jun 11, 2021

Imago BioSciences’ Bomedemstat Demonstrates Continued Encouraging Clinical Activity in Phase 2 Data for Treatment of Essential Thrombocythemia and Myelofibrosis at EHA 2021 Virtual Congress

Jun 11, 2021

Stuart Therapeutics Announces Start of Patient Enrollment in its Phase 2 Clinical Trial of ST-100 for Dry Eye Disease

Jun 10, 2021

Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

Jun 10, 2021

Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

Jun 9, 2021

Revolo Biotherapeutics Enters into Partnership Agreement with Northway Biotech to Manufacture its Novel Binding Immunoglobulin Protein, ‘1805, to Support Phase 2 Trials in Rheumatoid Arthritis and Uveitis

Jun 9, 2021

eFFECTOR Therapeutics Doses First Patient in Phase 2b KICKSTART Clinical Trial

Jun 9, 2021

InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm™ Program, Plans for Pivotal Phase 3 Study and Expansion of Senior Management Team

Jun 8, 2021

NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo (nivolumab)

Jun 4, 2021

Biosight Presents Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) in an Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 4, 2021

Tarveda Therapeutics Presents Promising Phase 2 Data of PEN-221 in Gastrointestinal Mid-gut Neuroendocrine Tumors

Jun 2, 2021

CalciMedica Publishes Positive Data from Phase 2a Study of Auxora™ in Patients with Acute Pancreatitis and Announces First Patients Dosed in Phase 2b Study

Jun 2, 2021

CalciMedica Publishes Positive Data from Phase 2a Study of Auxora in Patients with Acute Pancreatitis and Announces First Patients Dosed in Phase 2b Study

May 27, 2021

Disc Medicine Expands Hematology Pipeline with Worldwide Licensing Agreement for Bitopertin, a First-in-Class Modulator of Heme Synthesis

May 27, 2021

Cellphire Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Thrombosomes in Bleeding Thrombocytopenic Patients

May 26, 2021

NFlection Therapeutics' NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical Trial

May 26, 2021

AmMax Bio Announces First Patient Enrolled in Phase 2 Trial of AMB-05X For Tenosynovial Giant Cell Tumor (TGCT)

May 21, 2021

Humacyte Announces Positive Long-Term Follow-Up Data from Phase 2 Vascular Access Trial

May 21, 2021

Imago BioSciences to Present Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at 2021 European Hematology Association Virtual Congress

May 20, 2021

Tarveda Therapeutics to Present Data from Phase 2 Study of PEN-221 at 2021 ASCO Annual Meeting

May 20, 2021

Laurent Pharmaceuticals Completes Patients Enrollment in Phase 2 Study of LAU-7b for the Treatment of COVID-19

May 20, 2021

Xalud Therapeutics’ Lead Candidate, XT-150, Achieves Multiple Clinical Milestones in Pathologic Inflammation and Neuroimmunology Therapeutic Areas

May 19, 2021

Apexigen Announces Presentation of Phase 2 Clinical Data on CD40 Antibody, Sotigalimab (APX005M), in Combination Therapy for Metastatic Pancreatic Cancer at the ASCO 2021 Annual Meeting

May 18, 2021

Medicago and GSK Announce Positive Interim Phase 2 Results for Adjuvanted COVID-19 Vaccine Candidate

May 17, 2021

Knopp Biosciences Reports Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

May 13, 2021

Knopp Biosciences to Present Details of Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

May 12, 2021

Amylyx Pharmaceuticals Presents Trial Design of Global Phase 3 PHOENIX Study of AMX0035 in ALS at the European Network to Cure ALS (ENCALS) Meeting 2021

May 11, 2021

Biosight Completes Enrollment in Phase 2b Study of Aspacytarabine (BST-236) for First-Line Acute Myeloid Leukemia Therapy

May 11, 2021

Concentric Analgesics Announces Podium Presentation of Vocacapsaicin Clinical Data at 46th Annual ASRA Meeting

May 6, 2021

MoonLake Immunotherapeutics announces publication in The Lancet of impressive Phase 2b data showing its Tri-specific Nanobody Sonelokimab totally clears skin in almost 6 out of 10 patients with moderate to severe psoriasis USA - English France - Français USA - English Deutschland - Deutsch Brazil - Português USA - English España - español

May 6, 2021

MoonLake Immunotherapeutics annonce la publication dans The Lancet de données sidérantes de phase 2b montrant que son Nanobody Sonelokimab trispécifique a totalement éclairci la peau de près de 6 patients sur 10 atteints de psoriasis modéré à grave France - Français Deutschland - Deutsch USA - English España - español

May 6, 2021

MoonLake Immunotherapeutics announces publication in The Lancet of impressive Phase 2b data showing its Tri-specific Nanobody Sonelokimab totally clears skin in almost 6 out of 10 patients with moderate to severe psoriasis USA - English USA - Français USA - Deutsch USA - español

May 5, 2021

AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia

May 5, 2021

Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis

May 4, 2021

Alzheon Partners with Czech Institute of Organic Chemistry and Biochemistry to Develop First Alzheimer’s Diagnostic Assay for Measuring Neurotoxic Beta Amyloid Oligomers in Human Brain

May 3, 2021

Ichnos Sciences Presents Positive Data From Ongoing Phase 2b Study Of Telazorlimab In Atopic Dermatitis At The 2021 SID Virtual Meeting

Apr 30, 2021

Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study

Apr 30, 2021

Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study

Apr 29, 2021

Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients

Apr 28, 2021

Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2021 ASCO Annual Meeting

Apr 28, 2021

Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery USA - English USA - English

Apr 28, 2021

Pfizer Acquires Amplyx Pharmaceuticals

Apr 28, 2021

ReAlta Life Sciences Closes $20 Million Series A3 Financing to Advance Multiple Programs into Phase 2 Clinical Trials

Apr 28, 2021

Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery

Apr 25, 2021

Sirnaomics Initiates Phase 2b Study Using STP705 for Treatment of Squamous Cell Skin Cancer

Apr 23, 2021

Sagimet to Present Phase 2 Data on Lead Candidate TVB-2640 at The International Liver Congress™ 2021 (EASL)

Apr 23, 2021

Avillion's positive Phase 2 trial of tri-specific Nanobody sonelokimab (M1095) in chronic psoriasis published in The Lancet

Apr 22, 2021

Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b Trial of Oral SYK/JAK Inhibitor Gusacitinib at AAD VMX Late-Breaking Session

Apr 21, 2021

Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Apr 21, 2021

Antios Therapeutics Doses First Patients in SAVE 1, a Phase 2a Study of ATI-2173 in Patients with Chronic Hepatitis B Virus (HBV)

Apr 21, 2021

AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease

Apr 21, 2021

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

Apr 21, 2021

Brii Biosciences, Vir Biotechnology and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

Apr 18, 2021

Lyndra Therapeutics Presents Promising Phase 2 Data on Once-Weekly Oral Risperidone Treatment, LYN-005, in Development for Schizophrenia

Apr 18, 2021

Sirnaomics Initiates Phase 2 Study Using STP705 for Keloid Scar Prevention

Apr 16, 2021

Stuart Therapeutics Announces Receipt of Study May Proceed Letter from U.S. FDA for ST-100 Dry Eye Disease Phase 2 Clinical Trial

Apr 15, 2021

AFYX Therapeutics Presents Phase 2 Data of Rivelin-CLO at 2021 AAOM Virtual Conference

Apr 15, 2021

Anji Pharma Adds Clinical Sites to Accelerate Clinical Development of Pradigastat for the Treatment of Functional Constipation

Apr 14, 2021

OrphoMed’s ORP-101 Passes Second Planned Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients

Apr 13, 2021

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

Apr 12, 2021

Treovir Announces Positive Results of Phase 1 Study of G207 in Pediatric Patients with Recurrent High-Grade Glioma

Apr 10, 2021

Elevation Oncology Announces the Presentation of New Preclinical Data in Pancreatic and Cholangiocarcinoma PDX Models on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signaling

Apr 6, 2021

Elevation Oncology Announces Clinical Cancer Research Publication Highlighting the Specific Inhibition of HER3 by Seribantumab in Preclinical NRG1 Fusion Models

Apr 6, 2021

Mineralys Therapeutics Closes $40 Million Series A Funding

Apr 6, 2021

MitoImmune Received FDA Clearance of IND Application for MIT-001, a Novel Anti-Inflammatory/Anti-Necrotic Therapy for Oral Mucositis in CCRT patients with Head and Neck Cancer

Mar 31, 2021

Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2 Clinical Trial of PVSRIPO With and Without Immune Checkpoint Blockade in Advanced PD-1/L1 Refractory Melanoma

Mar 30, 2021

NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in Patients with High Grade Glioma

Mar 29, 2021

Gemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update

Mar 25, 2021

Visus Therapeutics Initiates Phase 2 Clinical Trial of BRIMOCHOL for the Treatment of Presbyopia

Mar 25, 2021

Apnimed Closes Series B Financing to Advance Once-Daily Oral Medication for Obstructive Sleep Apnea (OSA)

Mar 24, 2021

Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Sign Agreements to Conduct a Phase 2 Randomized, Window of Opportunity Trial in Early-Stage Breast Cancer

Mar 23, 2021

NeoImmuneTech Announces First Patient Dosed in Phase 2a Portion of Basket Study Evaluating NT-I7 (efineptakin alfa) and KEYTRUDA (pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors

Mar 22, 2021

BioAge Initiates Phase 2 Trial of BGE-175 to Treat COVID-19 by Reversing Immune Aging, a Key Cause of Morbidity and Mortality in Older Patients

Mar 22, 2021

BERG To Conduct Phase Two Trial For Treatment Of Deadly Glioblastoma Multiforme [GBM]

Mar 19, 2021

Amyndas Announces Positive Top-Line Phase 2 Results for Investigational AMY-101 in Adults With Periodontal Inflammation and Gingivitis

Mar 17, 2021

Versantis Announces Positive Phase 1b Results for VS-01 in Patients with Decompensated Cirrhosis

Mar 17, 2021

Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Mar 17, 2021

MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease

Mar 16, 2021

Elevation Oncology and NeoGenomics Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study

Mar 16, 2021

Visus Therapeutics Announces FDA Acceptance of IND for Presbyopia-Correcting Eye Drop

Mar 16, 2021

Cytocom Receives FDA Clearance of IND for Phase 2 Clinical Trial of CYTO-205 as Treatment for COVID-19

Mar 16, 2021

Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH

Mar 15, 2021

BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment

Mar 11, 2021

Renibus Therapeutics Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury

Mar 9, 2021

Cognito Therapeutics Announces Positive Phase 2 Results as First Digital Therapeutic to Improve Memory, Cognition, Functional Abilities and Reduce Brain Atrophy in Alzheimer’s Disease

Mar 8, 2021

Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease

Mar 8, 2021

AEON Biopharma Initiates Enrollment in Phase 2 Trial of ABP-450 for the Preventive Treatment of Migraine

Mar 6, 2021

Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

Mar 5, 2021

Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International Symposium 2021

Mar 5, 2021

Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases

Mar 3, 2021

Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies

Mar 3, 2021

eXIthera Pharmaceuticals Announces FDA Acceptance of IND Application for Phase 2 Trial of EP-7041 for Thrombosis Prevention in COVID-19 Patients

Mar 3, 2021

Karolinska Development’s portfolio company Forendo Pharma advances FOR-6219 to Phase 2 based on positive Phase 1 data

Mar 3, 2021

Azura Ophthalmics Announces Positive Topline Results From Phase 2 Program of the Company’s Investigational Treatment for Meibomian Gland Dysfunction

Mar 2, 2021

ViaCyte and Gore Expand Collaboration to Develop Novel Membrane and Device Technologies that Enhance Delivery of Cell Replacement Therapies for Diabetes

Mar 1, 2021

Oxular raises $37 million

Feb 25, 2021

BioAge Initiates Phase 2a Trial of BGE-117 in Elderly Patients with Unexplained Anemia

Feb 16, 2021

NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo (nivolumab)

Feb 16, 2021

Cytocom Updates Investigational New Drug Application for Phase 2 Clinical Trial of CYTO-205 for the Treatment of COVID-19

Feb 11, 2021

Retrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key Clinical Trial Data Readouts

Feb 10, 2021

Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic Variants

Feb 9, 2021

Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial with Regenerative Treatment for Fuchs Endothelial Corneal Dystrophy

Feb 4, 2021

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting

Feb 3, 2021

ViaCyte Announces Initiation of Phase 2 Study of Encapsulated Cell Therapy for Type 1 Diabetes Patients

Feb 1, 2021

Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy

Jan 28, 2021

ImmunityBio Announces Positive Phase 2 Results Showing That Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer

Jan 27, 2021

ViaCyte Appoints Michael Yang President and CEO and Provides Company Update

Jan 26, 2021

OS Therapies Receives Trial Approval From Children's Oncology Group for AOST2121 / OST31-164-01 An Open-Label Phase 2 Study of Maintenance Therapy With OST31-164 After Resection of Recurrent Osteosarcoma

Jan 26, 2021

Concentric Analgesics Announces Additional Positive Results from Phase 2 Clinical Trial of Vocacapsaicin (CA-008) in Total Knee Arthroplasty Surgery

Jan 22, 2021

BirchBioMed Inc. Announces Positive Topline Data from Phase 2 Study of FS2 for Treatment of Keloid Scars

Jan 21, 2021

AriBio Co., Ltd. Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001 in Mild to Moderate Alzheimer’s Patients

Jan 19, 2021

InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation

Jan 19, 2021

Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease

Jan 19, 2021

Apnimed Announces First Patient Dosed in a Second Phase 2 Clinical Trial with AD109, a Disease Modifying Candidate for Obstructive Sleep Apnea

Jan 17, 2021

Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

Jan 14, 2021

Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

Jan 7, 2021

Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devastating Pulmonary Disease

Jan 4, 2021

SanBio Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology

Dec 23, 2020

EOM Pharmaceuticals Announces Its Pre-IND Meeting Request With U.S. FDA to Evaluate Plans for a Phase 2 Clinical Trial of Its Investigational Dual-Acting, Broad-Spectrum Immunomodulator in COVID-19 Patients

Dec 23, 2020

Palvella Therapeutics Reports Top-Line Results from Pivotal Phase 2/3 VALO Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel in Patients with Pachyonychia Congenita

Dec 22, 2020

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Dec 21, 2020

Azura Ophthalmics Announces Primary Endpoints Met in Topline Results from Phase 2 Trial of the Company’s Investigational Treatment for Contact Lens Discomfort

Dec 20, 2020

Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer

Dec 16, 2020

Concentric Analgesics Announces Positive Topline Results from Phase 2 Clinical Trial of Vocacapsaicin (CA-008) in Total Knee Arthroplasty Surgery

Dec 15, 2020

Harmony Biosciences Enrolls First Patient In Phase 2 Trial Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willi Syndrome

Dec 15, 2020

HighTide Therapeutics to Present Phase 2 Results of HTD1801 in NASH Patients Co-Morbid with Type 2 Diabetes at NASH Summit

Dec 14, 2020

Eleusis Launches Clinical Development of Psychedelic Infusion Therapies for Major Depressive Disorder and Acquires Kalypso Wellness Centers

Dec 10, 2020

Cyrano Therapeutics Raises $12.8 Million to Complete Phase 2 Trial of CYR-064 for the Restoration of Chronic Smell and Flavor Loss

Dec 9, 2020

CG Oncology Announces First Patient Dosed in Phase 2 Clinical Trial of CG0070, an Oncolytic Immunotherapy, in Combination with KEYTRUDA (pembrolizumab) for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Dec 8, 2020

Sojournix Advances Phase 2 Clinical Trial of SJX‑653 for Menopausal Hot Flashes

Dec 7, 2020

Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA

Dec 7, 2020

ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies

Dec 7, 2020

Biosight Presents Updated New Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting

Dec 7, 2020

KBP Biosciences Meets Primary Endpoint for BLOCK-CKD Phase 2b Study of KBP-5074 for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney Disease Patients

Dec 5, 2020

Imago BioSciences’ Bomedemstat (IMG-7289) Shows Sustained Clinical Activity in Phase 2 Interim Data for Treatment of Myelofibrosis

Dec 3, 2020

Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company’s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020

Dec 1, 2020

Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613 (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue

Dec 1, 2020

LianBio Announces Clearance to Initiate in China the Phase 2a Trial of Infigratinib in Patients with Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma with FGFR2 Gene Amplification

Dec 1, 2020

Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613 (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft

Nov 30, 2020

Istari Oncology Announces First Patient Dosed in the LUMINOS-101 Phase 2 Clinical Trial of PVSRIPO in Combination with Pembrolizumab for Patients with Recurrent Glioblastoma

Nov 30, 2020

Imago BioSciences Expands Phase 2 Clinical Trial of Bomedemstat (IMG-7289) for the Treatment of Myelofibrosis into Hong Kong

Nov 30, 2020

Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF Biomarkers

Nov 24, 2020

Apnimed Announces First Patient Dosed in Phase 2 Clinical Trial with AD109, Lead Candidate for Treatment of Obstructive Sleep Apnea

Nov 20, 2020

DNAtrix Announces Positive Data from Phase 2 CAPTIVE (KEYNOTE-192) Study with DNX-2401 in Patients with Recurrent Glioblastoma Highlighted in an Oral Late-Breaking Presentation During Society for Neuro-oncology (SNO) Annual Meeting

Nov 20, 2020

AbCellera-Discovered Antibody Granted Interim Authorization by Health Canada as a Treatment for COVID-19

Nov 19, 2020

Day One Announces Preliminary Phase 1 Results for DAY101 in Pediatric Low-Grade Glioma, Receipt of Breakthrough Therapy Designation (BTD) and New Phase 2 Study

Nov 18, 2020

Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE

Nov 17, 2020

AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival

Nov 17, 2020

Cerebral Therapeutics Announces Enrollment of First Patient in a Multicenter Randomized Controlled Phase 2b Trial in Epilepsy

Nov 16, 2020

NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 2 Study of NT-I7 (efineptakin alfa) in combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer

Nov 15, 2020

BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator

Nov 13, 2020

InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020

Nov 10, 2020

TCR² Therapeutics Announces Partnership with ElevateBio to Expand TC-210 Manufacturing Capacity

Nov 9, 2020

DNAtrix Announces Multiple Data Presentations, Including Late-Breaking Phase 2 CAPTIVE (KEYNOTE-192) Data in Recurrent Glioblastoma, Planned for the Society for Neuro-oncology (SNO) Annual Meeting

Nov 7, 2020

EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th Clinical Trials in Alzheimer's Disease (CTAD) Meeting

Nov 5, 2020

Interim Data From Imago BioSciences’ Phase 2b Study of Bomedemstat (IMG-7289) for Treatment of Myelofibrosis to Be Presented at 62nd American Society of Hematology Annual Meeting

Nov 5, 2020

Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting

Nov 4, 2020

NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac for Intratumoral Treatment of Prostate Cancer

Nov 2, 2020

AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy

Nov 2, 2020

Neuraly Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 2B Trial of NLY01 for Patients with Alzheimer’s Disease

Oct 29, 2020

Positive results from Avillion's Phase 2 trial of sonelokinab (M1095) in chronic psoriasis to be presented today in Late-Breaking News Session at EADV 2020 Virtual

Oct 27, 2020

Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer’s Disease

Oct 27, 2020

Olatec Therapeutics Enrolls its First Patients in a Phase 2 Clinical Trial in COVID-19 with its Selective NLRP3 Inhibitor, Oral Dapansutrile

Oct 26, 2020

Cingulate Therapeutics Presents Results of Pivotal Phase 2 Clinical Trial for Lead ADHD Candidate CTx-1301 at the American Association of Child and Adolescent Psychiatry Annual Meeting

Oct 22, 2020

Phosplatin Therapeutics Doses First Patient in Phase 2 Study of PT-112 in Metastatic Castration Resistant Prostate Cancer Patients

Oct 22, 2020

Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases

Oct 22, 2020

F2G Receives Second US FDA Breakthrough Therapy Designation for Olorofim

Oct 22, 2020

Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease

Oct 21, 2020

Oxeia Biopharmaceuticals, Inc. Announces Initiation Of Phase 2 Trial For OXE103 For The Treatment Of Concussions

Oct 20, 2020

CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects

Oct 20, 2020

Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)

Oct 20, 2020

Asana BioSciences to Present Positive Results from Phase 2b Study of Oral JAK/SYK Inhibitor Gusacitinib in Patients with Chronic Hand Eczema in the Late-Breaking News Session at the EADV Virtual Congress

Oct 16, 2020

Amplyx to Present New Clinical and Preclinical Data for its Two Lead Programs at Upcoming Scientific Conferences

Oct 14, 2020

Meissa Vaccines Expands Leadership Team as Company Advances Intranasal RSV and COVID-19 Live Attenuated Vaccine Candidates

Oct 13, 2020

CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Expanded Phase 2 Study of Pancreatic Cancer Treatment

Oct 13, 2020

Sermonix Doses First Patient in Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib

Oct 13, 2020

Linnaeus Therapeutics Announces First Patient Dosed in Its Clinical Trial of LNS8801 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Cancer

Oct 8, 2020

Academic and Industry Collaborative Study, including Goldfinch Bio, Demonstrates Benefit of Proteinuria Reduction on Kidney Survival in Patients with Focal Segmental Glomerulosclerosis (FSGS)

Oct 6, 2020

EIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy bodies (DLB)

Oct 6, 2020

Talaris Therapeutics Closes $115 Million Series B Financing

Oct 6, 2020

Cerevel Therapeutics Announces First Patient Dosed in Phase 2 Trial of CVL-865, an Investigational Therapy in Development for the Treatment of Epilepsy

Oct 6, 2020

NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial; Opens Study to Patients Who Have Failed All Approved Standards of Care

Oct 6, 2020

Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD's The Liver Meeting Digital Experience™ 2020

Oct 1, 2020

Imago BioSciences Doses First Patient in Phase 2b Study of Bomedemstat (IMG-7289) in Essential Thrombocythemia

Sep 30, 2020

Carmot Therapeutics Expands Leadership Team and Closes $47 Million Series C Financing to Advance Novel Incretin Receptor Modulators Through Phase 2 Studies

Sep 30, 2020

Elevation Oncology and US Oncology Research Announce Collaboration to Expand Genomic Testing of Solid Tumors and Local Site Activation in Support of the Phase 2 CRESTONE Study

Sep 25, 2020

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

Sep 23, 2020

Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn's disease

Sep 22, 2020

Axial Biotherapeutics Appoints Federico Bolognani, M.D., Ph.D., Vice President and Head of Clinical Science

Sep 22, 2020

ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA (pembrolizumab) in Patients with Head and Neck Cancer

Sep 21, 2020

Sojournix Announces Publication of Results from SJX-653 Proof-of-Mechanism Study in The Journal of Clinical Endocrinology and Metabolism

Sep 18, 2020

BERG To Present Discovery/Validation Of Biomarkers Associated With Survival In Pancreatic Ductal Adenocarcinoma (PDAC) Treated With BPM 31510-IV At The European Society For Medical Oncology (ESMO) 2020 Congress

Sep 17, 2020

IO Biotech Announces Late-Breaking Oral Presentation of Phase 2 Clinical Melanoma Data Including Complete Response (CR) Rate of 45 Percent

Sep 17, 2020

Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb’s Yervoy in a Phase 2 Study

Sep 17, 2020

Apnimed Successfully Completes Phase 1 Study in Lead Program for Obstructive Sleep Apnea

Sep 16, 2020

Interim Data Reported for AbCellera-Discovered COVID-19 Antibody in Phase 2 Clinical Trials

Sep 16, 2020

Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma

Sep 14, 2020

Blade Therapeutics Reaches Enrollment Goal for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients With COVID-19 Pneumonia

Sep 14, 2020

NASIR-HCC: Phase 2 study of Sirtex Medical SIR-Spheres Y-90 resin microspheres followed by Nivolumab therapy demonstrates favorable safety and tolerability profile at ILCA 2020

Sep 14, 2020

Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis

Sep 11, 2020

Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma

Sep 10, 2020

Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration

Sep 10, 2020

Avillion announces positive top-line results of Phase 2 trial of sonelokinab (M1095), an anti-IL-17 A/F Nanobody, in chronic psoriasis

Sep 9, 2020

Intensity Therapeutics Doses First Patients with Combination of INT230-6 and Merck’s Keytruda in Phase 2 Studies

Sep 9, 2020

AZTherapies Doses First Patient in Phase 2a Study of ALZT-OP1a in Amyotrophic Lateral Sclerosis (ALS)

Sep 8, 2020

Goldfinch Bio Initiates Phase 2 Clinical Trial Evaluating Novel Drug Candidate GFB-887 as a Precision Medicine for Patients with Kidney Diseases

Sep 8, 2020

LIPAC Oncology Announces Completion of Phase 2A Clinical Trial of LiPax in Patients with Non-Muscle Invasive Bladder Cancer

Sep 2, 2020

LB Pharmaceuticals Inc Announces the Hiring of Dr. Anna Eramo as Chief Medical Officer

Sep 2, 2020

AEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment

Aug 31, 2020

Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2 Study of EMB-001 in Cocaine Use Disorder

Aug 31, 2020

Ashvattha Therapeutics Subsidiary Orpheris Enrolls First Patients in Phase 2 PRANA Clinical Study Evaluating OP-101 for Severe COVID-19

Aug 27, 2020

Laurent Pharmaceuticals Receives Approval from FDA to Initiate its COVID-19 Phase 2 Clinical Trial in the United States

Aug 26, 2020

Phosplatin Therapeutics Completes $18.4 Million Private Financing Round

Aug 25, 2020

Partner Therapeutics Initiates Patient Enrollment in U.S. Clinical Trial Evaluating Leukine (rhuGM-CSF, sargramostim) in COVID-19 Patients

Aug 20, 2020

Cytocom, Inc. Announces Agreement to Reacquire Rights to Lead Drug Candidate CYTO-201 and CYTO-401 in Emerging Markets

Aug 18, 2020

Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer

Aug 17, 2020

Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients English English

Aug 17, 2020

Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients

Aug 12, 2020

Blade Therapeutics Updates Enrollment Progress for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients with COVID-19 Pneumonia

Aug 12, 2020

Treadwell Announces Initiation of Phase 2 Study of CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer (TNBC): IND.239

Aug 11, 2020

Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis

Aug 11, 2020

Caris Life Sciences Partners with Elevation Oncology to Advance Enrollment in Phase 2 Trial of Patients with Solid Tumors Harboring NRG1 Gene Fusions

Aug 9, 2020

AnHeart Announces Entry into Series A+ Equity Financing Agreements

Aug 5, 2020

BioAegis Therapeutics Initiates Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment

Aug 5, 2020

KBP Biosciences Doses Final Patient in BLOCK CKD Phase 2b Study of KBP-5074

Jul 30, 2020

Sound Pharmaceuticals files IND to test SPI-1005 in Phase 2 COVID-19 trials

Jul 30, 2020

Imago BioSciences Granted Access by European Medicines Agency to PRIME Scheme for IMG-7289 (Bomedemstat) in Myelofibrosis

Jul 28, 2020

Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivint in Patients with Desmoid Tumors

Jul 27, 2020

PolyPid to Present Phase 2 Results of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Conference Recorded Sessions

Jul 27, 2020

PolyPid to Present Phase 2 Results of D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Surgery at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Conference Recorded Sessions

Jul 27, 2020

jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa

Jul 22, 2020

Terns Pharmaceuticals Announces Initiation of Patient Dosing in the LIFT Study, a Phase 2a Clinical Trial of TERN-101 in Development for NASH

Jul 21, 2020

Biosight Announces Clinical Trial Collaboration with the European Cooperative Group, Groupe Francophone des Myélodysplasies

Jul 21, 2020

First Patient Dosed with Taletrectinib in AnHeart Phase 2 Trial of Non-Small Cell Lung Cancer with ROS1 Fusion

Jul 21, 2020

Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors Harboring Rare Genetic Driver Alterations

Jul 21, 2020

UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2

Jul 20, 2020

Amplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix

Jul 20, 2020

NeoImmuneTech Receives U.S. FDA Clearance of IND Application for Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo (nivolumab)

Jul 16, 2020

Imvax Inc. Raises $112 Million in Series C Financing

Jul 15, 2020

BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment

Jul 8, 2020

Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer

Jul 7, 2020

Ridgeback Biotherapeutics Announces Potential COVID-19 Treatment EIDD-2801 Will Leverage Innovative Testing Platform AGILE for Phase 2 Trial

Jul 7, 2020

jCyte Inc. Announces Presentation of Phase 2b Results Evaluating jCell in Retinitis Pigmentosa at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting

Jun 30, 2020

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults USA - English USA - English

Jun 30, 2020

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults USA - English India - English

Jun 29, 2020

Cytocom, Inc. Announces Successful Completion of Type-B Pre-IND Meeting with FDA Regarding Proposed Phase 2 Clinical Trial of CYTO-201 in COVID-19 Patients

Jun 29, 2020

KBP Biosciences Announces Peer-Reviewed Publication of Trial Design Manuscript for Ongoing BLOCK CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension

Jun 24, 2020

HemoShear Therapeutics Receives FDA Clearance of IND for Phase 2 Study of its Investigational Drug HST5040 for the Treatment of Methylmalonic Acidemia and Propionic Acidemia

Jun 19, 2020

Ridgeback Biotherapeutics Announces Launch of Phase 2 Trials Testing EIDD-2801 as Potential Treatment for COVID-19

Jun 18, 2020

Terns Pharmaceuticals Initiates the LIFT Study, a Phase 2a Clinical Trial of TERN-101 for the Treatment of NASH

Jun 17, 2020

Sagimet Announces Positive Topline Results in 12-week NASH Phase 2 Clinical Trial of FASN Inhibitor TVB-2640

Jun 17, 2020

AriBio Announces Completion of Enrollment in Phase 2 Alzheimer’s Study with AR1001

Jun 16, 2020

Vyome Therapeutics Announces Positive Results in Phase 2 Trial of VB-1953 for Moderate to Severe Acne

Jun 16, 2020

Oncologie Announces Key Updates and Planned Activities for its Clinical Programs and RNA-based Biomarker Platform

Jun 15, 2020

Tarsus Pharmaceuticals Announces Positive Results of the Mars study, a Phase 2a Study of the Efficacy and Safety of TP-03 to Treat Demodex Blepharitis, at ARVO 2020 Virtual Meeting

Jun 10, 2020

F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP Designation for Multiple Fungal Infections

Jun 9, 2020

Leading BioSciences Teams with Donnelley Financial Solutions to Create Innovative Study Tool for Clinical Trial Monitoring During COVID-19 Pandemic

Jun 9, 2020

Vedanta Biosciences Announces Positive Topline Data from Two Phase 1 Studies of VE202, a Rationally Defined Bacterial Consortium Being Advanced for Inflammatory Bowel Diseases (IBD)

Jun 8, 2020

Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer's Clinical Trials Consortium

Jun 3, 2020

Complexa Completes Patient Enrollment in Phase 2 FIRSTx Trial Evaluating CXA-10 in Focal Segmental Glomerulosclerosis, a Rare and Severe Form of Kidney Disease

Jun 2, 2020

Asana BioSciences Announces Positive Topline Results from Phase 2b Study of Oral JAK/SYK Inhibitor Gusacitinib (ASN002) in Patients with Chronic Hand Eczema: Rapid and Significant Improvement Demonstrated

Jun 1, 2020

Alkahest Announces Initiation of Phase 2 Study AKST1210-201 Exploring Treatment of Cognitive Impairment in End Stage Renal Disease Patients

Jun 1, 2020

Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells

May 30, 2020

MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients

May 28, 2020

MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613 (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia

May 28, 2020

WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo) for the Treatment of Non-Small Cell Lung Cancer

May 28, 2020

Bird Rock Bio Files IND Application for Phase 2 Study of Nimacimab for Treatment of Renal Diseases

May 28, 2020

Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients

May 26, 2020

Imago BioSciences To Present Update on Phase 2 results of Bomedemstat (IMG-7289), a Lysine Specific Demethylase-1 (LSD1) Inhibitor for the Treatment of Myelofibrosis (MF)

May 22, 2020

Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis

May 21, 2020

WindMIL Therapeutics Opens Combination Therapy Portion of its Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer

May 20, 2020

KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study of KBP-5074

May 19, 2020

Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix

May 15, 2020

Leading BioSciences Receives IND Clearance for Phase 2 COVID-19 Study

May 14, 2020

NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer

May 7, 2020

Oculis Announces Presentation of Results From Its Phase 2 (SKYGGN) Trial of OCS-01 for Inflammation and Pain Following Cataract Surgery at Upcoming ASCRS Annual Meeting 2020

May 7, 2020

HighTide Therapeutics Announces Positive Topline Results From Phase 2a Study of HTD1801 in NASH Patients

May 6, 2020

Galecto Advances Phase 2b Study of GB0139 in Idiopathic Pulmonary Fibrosis Recruitment Remains on Track Despite COVID-19 Crisis

May 4, 2020

University of Oxford and Sound Pharmaceuticals complete Phase 2 Bipolar Disorder Study with SPI-1005

May 4, 2020

Viriom Announces Initiation of Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation of VM1500A in HIV-Infected Patients

Apr 22, 2020

AFYX Therapeutics Achieves Primary Endpoint in Phase 2b Trial of Rivelin-CLO in Patients with Oral Lichen Planus

Mar 31, 2020

Data on Sagimet's Lead Candidate TVB-2640 to be Presented at EASL ILC 2020

Mar 26, 2020

RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress

Mar 26, 2020

RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress English English English

Mar 26, 2020

RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress USA - English Israel - English

Mar 24, 2020

OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company's Lead Investigational Drug in Frontline Ovarian Cancer

Mar 24, 2020

Leading BioSciences Announces Top Line Phase 2 Data Demonstrating LB1148 Achieves Primary Endpoint with Statistically Significant Improvement in Bowel Function Following Cardiovascular Surgery

Mar 12, 2020

Engage Therapeutics Announces Phase 2b StATES Study of Staccato Alprazolam for Seizure Cessation Meets Primary Endpoint

Mar 10, 2020

Asana BioSciences Announces Topical Sodium Channel Blocker ASN008 Achieves Positive Results for the Treatment of Pruritus in Atopic Dermatitis; and Provides Update on JAK/SYK Inhibitor Gusacitinib in Phase 2 Studies for Chronic Hand Eczema and AD

Mar 9, 2020

F2G Receives US FDA Orphan Drug Designation for Olorofim

Mar 3, 2020

CORRECTING and REPLACING Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease

Feb 27, 2020

Harbour BioMed Receives U.S. FDA IND Approval for Phase 2 Clinical Trial and Orphan Drug Designation for Anti-PD-L1 Monoclonal Antibody, HBM9167

Feb 27, 2020

Clene Nanomedicine Presents Blinded Interim Data from the VISIONARY-MS Phase 2 Study

Feb 25, 2020

IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer

Feb 24, 2020

Sojournix Announces Initiation of Phase 2 Clinical Trial of SJX-653, a Novel Selective NK3 Antagonist for Menopausal Hot Flashes

Feb 20, 2020

Dyve Biosciences Announces First Patient Enrolled in TARGETS Study for Treatment of Acute Gout

Feb 13, 2020

Enrollment Begins for Latiglutenase (IMGX003) Phase 2b Trial for Treatment of Celiac Disease

Feb 12, 2020

Longeveron LLC Announces Completion of Enrollment in Phase 2b Clinical Trial of Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs) in Aging Frailty.

Feb 11, 2020

Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients

Feb 11, 2020

T3D Therapeutics Begins Enrollment in the PIONEER Phase 2 Clinical Trial of T3D-959 in Patients with Mild to Moderate Alzheimer's Disease

Feb 10, 2020

Alkahest Announces Initiation of Phase 2b Clinical Trial of AKST4290 in Patients with Treatment-Naive Wet Age-Related Macular Degeneration

Feb 4, 2020

Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in Parkinson’s Disease with Funding from The Michael J. Fox Foundation

Feb 4, 2020

AIVITA Biomedical Completes Patient Recruitment in Phase 2 GBM Trial

Jan 24, 2020

BERG Presents Initial Clinical Data And Identification Of Response Biomarkers In A Phase 2 Pancreatic Cancer Trial Guided By Using The Interrogative Biology Platform At ASCO-GI Meeting

Jan 23, 2020

BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders

Jan 22, 2020

Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals

Jan 13, 2020

KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814

Jan 9, 2020

ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jan 9, 2020

Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration

Jan 9, 2020

ADC Therapeutics annonce des résultats positifs du test clinique pivot de phase 2 du loncastuximab tesirine (ADCT-402) en monothérapie chez des patients atteints d'un lymphome à grandes cellules B diffuses en rechute ou réfractaire

Jan 8, 2020

PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma

Jan 7, 2020

Cerebral Therapeutics Completes $35 Million Series B Financing

Jan 6, 2020

Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for a Phase 2 Clinical Trial of LYR-210 for Chronic Rhinosinusitis

Jan 6, 2020

ZyVersa Therapeutics' CEO, Stephen C. Glover to Attend the 38th Annual J.P. Morgan Healthcare Conference 2020

Dec 19, 2019

Embera NeuroTherapeutics Completes Series B Financing and Receives Grants to Advance EMB-001 into Phase 2 Clinical Studies in Cocaine Use Disorder and Smoking Cessation

Dec 18, 2019

Qu Biologics Completes Enrollment in First Stage of Phase 2 Clinical Trial in Moderate to Severe Crohn’s Disease

Dec 12, 2019

WindMIL Therapeutics Announces Dosing of First Patient in a Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer

Dec 11, 2019

BlackThorn Therapeutics Reports Data Supporting Phase 2 Development of KOR Antagonist, BTRX-335140, in Depression and Other CNS Disorders

Dec 11, 2019

Biothera Pharmaceuticals Presents Updated Phase 2 Data for Chemo-refractory Triple Negative Breast Cancer Patients at San Antonio Breast Cancer Symposium

Dec 10, 2019

Dyve Biosciences Receives FDA Clearance to Begin Phase 2 Study of DYV-700 for Treatment of Acute Gout Pain

Dec 10, 2019

ADC Therapeutics annonce la présentation orale des données d'efficacité intermédiaires de l'essai clinique pivot de phase 2 de l'ADCT-402 (loncastuximab tesirine) chez des patients atteints de lymphomes diffus en rechute ou réfractaires à grandes cellules B lors de la 61e réunion annuelle de l'ASH

Dec 9, 2019

Alkahest Presents Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease

Dec 9, 2019

ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting

Dec 6, 2019

Enteris BioPharma's Licensing Partner, Cara Therapeutics, Announces Top Line Data from Phase 2 Trial of Peptelligence-Engineered Oral KORSUVA™ for the Treatment of Pruritus in Patients with Advanced Chronic Kidney Disease (CKD)

Dec 5, 2019

EIP Pharma Announces Presentation of Phase 2b Clinical Trial Results of Neflamapimod in Early-stage Alzheimer's Disease at Clinical Trials in Alzheimer's Disease (CTAD) meeting

Dec 4, 2019

Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s Disease

Dec 4, 2019

Biothera Pharmaceuticals Phase 2 Triple Negative Breast Cancer Data Selected for Spotlight Session at San Antonio Breast Cancer Symposium

Dec 3, 2019

Censa Pharmaceuticals Announces CNSA-001 Met Primary and Secondary Endpoints in Phase 2 Trial in Patients with PKU

Dec 2, 2019

Knopp Biosciences and University of Leicester Announce Update on Planned Phase 2 Clinical Trial of Oral Dexpramipexole in Severe Eosinophilic Asthma

Dec 2, 2019

Alkahest to Present New Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease at the Clinical Trials in Alzheimer’s Disease (CTAD) Conference

Dec 2, 2019

Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613® (devimistat) for Patients with Relapsed or Refractory Burkitt’s Lymphoma/Leukemia to Massachusetts General Hospital in Boston

Dec 2, 2019

Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613 (devimistat) for Patients with Relapsed or Refractory Burkitt’s Lymphoma/Leukemia to Massachusetts General Hospital in Boston

Nov 24, 2019

DNAtrix Presents Positive Results from the Phase 2 CAPTIVE/KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting

Nov 19, 2019

Biosight Announces Data to be Presented at ASH 2019 Annual Meeting

Nov 19, 2019

Biosight Announces Data to be Presented at ASH 2019 Annual Meeting English English

Nov 19, 2019

Biosight Announces Data to be Presented at ASH 2019 Annual Meeting USA - English USA - English

Nov 19, 2019

Faraday Pharmaceuticals Announces Positive Top-Line Results from Phase 2 Trial of FDY-5301 for Treatment of Reperfusion Injury Following a STEMI Heart Attack

Nov 18, 2019

Amygdala Neurosciences Announces $5.6M Financing and Dr. Mack Mitchell's Expanded Role as CMO

Nov 12, 2019

AIVITA Biomedical Announces New Positive Phase 2 Glioblastoma Data at SITC Annual Meeting Podium Presentation

Nov 12, 2019

Knopp Biosciences to Present at Piper Jaffray 31st Annual Healthcare Conference

Nov 12, 2019

Faraday Pharmaceuticals Announces Presentation of Clinical Data from Phase 2 Trial of FDY-5301 at the American Heart Association Scientific Sessions 2019

Nov 12, 2019

Positive data from Sanifit’s Phase 2b CaLIPSO trial of SNF472 published in Circulation

Nov 11, 2019

DNAtrix to Present Updated Results from the Phase 2 CAPTIVE / KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting

Nov 11, 2019

Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World’s First Stem Cell Therapy Trial using HepaStem™ in Acute-on-Chronic Liver Failure

Nov 11, 2019

F2G Receives US FDA Breakthrough Therapy Designation for Olorofim

Nov 8, 2019

Brain Cancer Patient Survival, Immune and Tumor Data from AIVITA Biomedical's Phase 2 Clinical Trial to be Presented at SITC Annual Meeting

Nov 8, 2019

Cirius Therapeutics Announces Results from Phase 2b NASH Study Supporting Advancing to Phase 3 Development of MSDC-0602K; Data Accepted for Late Breaker Presentation at The Liver Meeting

Nov 8, 2019

Biothera Pharmaceuticals to Present Immune Pharmacodynamic Data (IPD) Showing Immune Activation in Phase 2 Melanoma and Triple Negative Breast Cancer Study

Nov 7, 2019

EIP Pharma Announces U.S. FDA Grants Fast-Track Designation to Neflamapimod as a Treatment for Dementia with Lewy Bodies (DLB)

Nov 7, 2019

EIP Pharma Announces Clinical Trial Results of REVERSE-SD, a Phase 2b Study of Neflamapimod in Early-stage Alzheimer's Disease

Nov 5, 2019

Palladio Biosciences Announces Presentations of ELiSA Phase 2 Study Results and Phase 3 Lixivaptan Clinical Program Design during the American Society of Nephrology Kidney Week 2019 Meeting

Nov 5, 2019

Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study

Nov 5, 2019

Vyome Therapeutics Completes Enrollment of Phase 2 Clinical Trial with VB-1953 in Moderate to Severe Inflammatory Acne

Nov 4, 2019

Ichnos Sciences Announces Completion Of Enrollment Of Phase 2b Trials For Two Investigational Therapies - ISB 830 And ISC 27864

Nov 4, 2019

T3D Therapeutics Closes $15M Financing to Advance Phase 2 Development of T3D-959 in a New Approach to Treating Alzheimer's Disease.

Nov 1, 2019

Promentis Pharmaceuticals to Present at the 10th Anniversary CNS Summit

Oct 31, 2019

Promentis Pharmaceuticals Announces Positive Results for Phase 2A Study of SXC-2023 Targeting Novel Glutamatergic Mechanism and Completion of Enrollment for Phase 2 Trichotillomania Study

Oct 30, 2019

Sanifit announces that Phase 2b CaLIPSO trial of SNF472 met its primary endpoint

Oct 25, 2019

Imago BioSciences Preliminary Data from Ongoing Phase 2 Study of IMG-7289 for the Treatment of Myelofibrosis to be Presented at the 61st American Society of Hematology Annual Meeting & Exposition

Oct 25, 2019

Imago BioSciences Preliminary Data from Ongoing Phase 2 Study of IMG-7289 for the Treatment of Myelofibrosis to be Presented at the 61st American Society of Hematology Annual Meeting and Exposition

Oct 25, 2019

LIPAC Oncology Announces Successful Completion of Phase 1 Bladder Cancer Clinical Study and Initiation of Phase 2A Study

Oct 24, 2019

Brain Cancer Patients Display Appropriate Immune Responses and Decreasing Tumor Biomarkers in AIVITA Biomedical's Phase 2 Clinical Trial

Oct 21, 2019

Amygdala Neurosciences Awarded $1.35 million NIH Grant to Conduct Long Term, Phase 3 Enabling, Toxicology Studies

Oct 21, 2019

Cirius Therapeutics' Phase 2b Data of MSDC-0602K for the Treatment of NASH Accepted as a Late-Breaking Oral Presentation at The Liver Meeting

Oct 17, 2019

Amygdala Neurosciences Announces Dosing of the First Patient in the NIH Funded Phase 2 Proof-Of-Concept study of ANS-6637 for the Treatment of Alcohol Use Disorder

Oct 17, 2019

Cadent Therapeutics Appoints Christopher Kenney, M.D. as Chief Medical Officer and Provides Clinical Update

Oct 17, 2019

Bird Rock Bio Announces Successful Completion of Phase 1B Safety Study and Readiness for Phase 2B Study of Nimacimab in Patients with Diabetic Kidney Disease

Oct 17, 2019

ADC Therapeutics Doses First Patients in Pivotal Phase 2 Clinical Trial of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma

Oct 17, 2019

ADC Therapeutics administre aux premiers patients de l'essai clinique intermédiaire de phase 2 de l'ADCT-301 chez les patients atteints d'un lymphome de Hodgkin récidivant ou réfractaire

Oct 17, 2019

Aristea Therapeutics Announces the Completion of Enrollment in RIST4721-201, a Phase 2a Proof-of-Concept Study of RIST4721 for the treatment of Palmoplantar Pustulosis (PPP)

Oct 16, 2019

PolyPid Announces Positive Top-line Results from Phase 2 Clinical Trial of D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Surgery

Oct 15, 2019

Denovo Biopharma Receives FDA's Permission to Proceed with a Biomarker-Guided Phase 2b Clinical Trial with DB102 (Enzastaurin) In First-Line Treatment of Glioblastoma (GBM)

Oct 11, 2019

CORRECTING and REPLACING Harbour BioMed Announces Completion of Phase 2 Study in China of HBM9036 In Patients With Moderate-to-Severe Dry Eye Disease

Oct 10, 2019

Forbius: Phase 2 Clinical Data with Tumor-Selective Anti-EGFR ADC AVID100 Featured at AACR-NCI-EORTC and World ADC San Diego

Oct 10, 2019

Frequency Therapeutics Commences Dosing in its Phase 2a Study of FX-322 for Sensorineural Hearing Loss; FDA Grants FX-322 Fast Track Designation

Oct 10, 2019

Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopia

Oct 9, 2019

Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer

Oct 4, 2019

Amylyx Pharmaceuticals Announces Last Patient Completes Last Study Visit in CENTAUR Phase 2 Study of AMX0035 in ALS

Oct 2, 2019

AIVITA Biomedical Announces Publication Concerning a Predictive Biomarker for Melanoma Patients Treated with the Company's Platform Immunotherapy

Oct 2, 2019

Graybug Vision Initiates Phase 2b (ALTISSIMO) Clinical Trial of GB-102 in Patients with Wet Age-Related Macular Degeneration

Oct 1, 2019

Immunomic Therapeutics Assumes Sponsorship of ATTAC-II IND for ITI-1000, a Dendritic Cell Vaccine in Phase 2 for the Treatment of GBM

Sep 30, 2019

Ayala Pharmaceuticals Presents Encouraging Preliminary Safety and Efficacy Data in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with Progressing Disease and Notch Activating Mutations from Ongoing Phase 2 Clinical Trial at ESMO

Sep 23, 2019

Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back

Sep 23, 2019

Cerevel Therapeutics Announces Positive Results from a Phase 2 Study of Tavapadon in Patients with Early-stage Parkinson’s Disease

Sep 23, 2019

Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

Sep 23, 2019

AVEO Oncology and EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma

Sep 19, 2019

Cerevel Therapeutics to Present Results from a Phase 2 Study of Tavapadon in Patients with Early-stage Parkinson’s Disease

Sep 19, 2019

Spruce Biosciences Announces Positive Results from 12-week, Phase 2a Study of Tildacerfont in Adults with Congenital Adrenal Hyperplasia

Sep 17, 2019

Arix Bioscience plc: Amplyx Unveils Expanded Pipeline and Reports Phase 2 Data from Lead Programme

Sep 17, 2019

Clene Nanomedicine, Inc. Awarded $1.37M AUD Grant from FightMND to Conduct Phase 2 Clinical Study for the Treatment of Amyotrophic Lateral Sclerosis

Sep 16, 2019

Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia

Sep 16, 2019

Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients

Sep 16, 2019

Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX2-73 in Patients with Rett Syndrome

Sep 9, 2019

MicuRx Pharmaceuticals Reports Positive Top-Line Results From a US Phase 2 ABSSSI Clinical Trial of Novel Antibiotic Contezolid Acefosamil

Sep 3, 2019

Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the 19th EURETINA Congress and The Retina Society 2019 Annual Meeting

Aug 21, 2019

Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence to Advance Development of Oral KORSUVA™

Aug 20, 2019

Landos Biopharma Announces First Patient Dosed in Global Phase 2 Clinical Trial of BT-11 in Mild to Moderate Ulcerative Colitis

Aug 19, 2019

Knopp Biosciences Announces Start of Phase 2 Clinical Trial Evaluating Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

Aug 19, 2019

Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD

Aug 19, 2019

Alkahest Initiates Phase 2 Clinical and Mechanistic Trial of Postoperative Recovery Following Primary Hip or Knee Arthroplasty

Aug 14, 2019

Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical's Phase 2 Clinical Trial

Aug 13, 2019

Landos Biopharma Completes $60 Million Series B Financing

Aug 12, 2019

Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.

Aug 12, 2019

PolyPid Completes Enrollment of Phase 2 Clinical Trial with D-PLEX100 in Abdominal Surgery

Aug 12, 2019

PolyPid Completes Enrollment of Phase 2 Clinical Trial with D-PLEX100 in Abdominal Surgery English English

Aug 8, 2019

ORIC Pharmaceuticals Announces Completion of $55 Million Mezzanine Financing to Advance Pipeline of Novel Therapies Targeting Cancer Resistance

Aug 6, 2019

Emergo Therapeutics announces successful completion of Phase 2a trial

Aug 5, 2019

Alkahest Announces Positive Top-line Data from Phase 2 Study in Mild to Moderate Alzheimer’s Disease 

Jul 31, 2019

Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX2-73 in Patients with Rett Syndrome

Jul 31, 2019

Sermonix Pharmaceuticals Closes US$26 Million Series A Financing Round Led by WILD Family Office

Jul 29, 2019

Rainier Therapeutics Announces Vofatamab FIERCE-22 Data Accepted for Presentation at ESMO 2019 Annual Congress

Jul 29, 2019

Alkahest Phase 2a Study AKST4290-202 in Refractory Neovascular AMD meets Primary and Secondary Endpoints

Jul 24, 2019

Allegro Ophthalmics to Present for the First Time the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the ASRS Annual Meeting 2019

Jul 15, 2019

Alkahest to Present New Data from Phase 2a Study of AKST4290 in Refractory Neovascular AMD at the 2019 American Society of Retina Specialists Annual Meeting

Jul 11, 2019

Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis

Jul 9, 2019

Celsius Therapeutics Signs Collaboration Agreement with Janssen to Identify Response Biomarkers for Ulcerative Colitis

Jul 8, 2019

AIVITA Biomedical Announces New Clinical Data in Ongoing Phase 2 Brain Cancer Trial

Jul 2, 2019

Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)

Jul 2, 2019

Monopar Therapeutics and the Spanish Sarcoma Group (GEIS) Team Up on Phase 2 Sarcoma Trial With Monopar's Novel Camsirubicin

Jun 27, 2019

Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Second Pruritus Phase 2 Trial of Peptelligence-Engineered Oral KORSUVA™

Jun 27, 2019

Oxthera Presents Continuous Strong Data from an Interim Analysis of Its Phase 2 Study With Oxabact in Primary Hyperoxaluria USA - English France - Français España - español Deutschland - Deutsch

Jun 27, 2019

Oxthera Presents Continuous Strong Data from an Interim Analysis of Its Phase 2 Study With Oxabact in Primary Hyperoxaluria USA - English USA - Français USA - español USA - Deutsch

Jun 27, 2019

Oxthera présente des données solides continues issues d'une analyse intérimaire de son étude de phase 2 avec Oxabact sur l'hyperoxalurie primaire USA - Français USA - español USA - English USA - Deutsch

Jun 25, 2019

WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs™) in Non-Small Cell Lung Cancer

Jun 25, 2019

Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere's Disease clinical trial

Jun 25, 2019

Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX2-73 in Patients for Rett Syndrome

Jun 25, 2019

ImmusanT Discontinues Phase 2 Clinical Trial for Nexvax2 in Patients With Celiac Disease

Jun 24, 2019

AFYX Therapeutics Closes $13 Million Convertible Loan Financing

Jun 18, 2019

Imara Presented Positive, Interim Phase 2a Data on IMR-687 for the Treatment of Sickle Cell Disease at the 24th Congress of the European Hematology Association

Jun 18, 2019

Arix Bioscience plc: Imara Presents initial Phase 2a data for IMR-687

Jun 17, 2019

Neurana Pharmaceuticals Announces Completion of Enrollment in the Phase 2 Study of Tolperisone in Acute Muscle Spasms of the Back

Jun 17, 2019

Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in Myelofibrosis Patients Failed/Ineligible for Ruxolitinib at the 24th European Hematology Association Annual Congress

Jun 17, 2019

Data Presented At 24ᵗʰ Congress of the European Hematology Association Demonstrates Clinical Safety, Early Efficacy of Imago BioSciences' IMG-7289 in Myelofibrosis Patients

Jun 13, 2019

Corvidia Therapeutics Initiates Phase 2b Dose-Finding Study for Ziltivekimab

Jun 13, 2019

Updates on Development of AMO Pharma's AMO-02 Presented at International Myotonic Dystrophy Consortium Meeting

Jun 11, 2019

AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT

Jun 8, 2019

Dance Biopharm Presents Encouraging Data from Phase 2 Clinical Trial of Dance 501 Inhaled Insulin Therapy at American Diabetes Association Meeting

Jun 7, 2019

NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough

Jun 5, 2019

Vaccitech Universal Flu Vaccine Passes Phase 2b Clinical Development Milestones

Jun 4, 2019

Dance Biopharm to Present Data from Phase 2 Clinical Trial of Dance 501 Inhaled Insulin Therapy at American Diabetes Association Meeting

Jun 4, 2019

Allegro Ophthalmics Announces Positive Topline Vision Results of Phase 2 Study Evaluating Risuteganib in Patients with Intermediate Dry Age-Related Macular Degeneration

Jun 3, 2019

NeuroRX to Present Phase 2 Efficacy Data for NRX-101 at 2019 BIO International Convention

Jun 1, 2019

Biothera Pharmaceuticals Presents Clinical Data from Phase 2 Study Evaluating the Combination of Imprime PGG and Merck’s KEYTRUDA in Triple Negative Breast Cancer at 2019 ASCO Annual Meeting

Jun 1, 2019

Rakuten Medical Releases Phase 2a Study Data during ASCO Annual Meeting Highlighting Positive Safety Profile and Clinically Meaningful Anti-tumor Activity

May 31, 2019

AIVITA Biomedical to Present at 2019 BIO International Convention Detailing New Clinical Data from Phase 2 Glioblastoma Trial

May 30, 2019

NeuroRx Reports Phase 2 Efficacy for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression

May 29, 2019

Akero Therapeutics Initiates Phase 2a Clinical Trial of Investigational Therapy AKR-001 for the Treatment of NASH

May 23, 2019

Cadent Therapeutics Receives Milestone Payment for Initiation of Phase 2 Trial of MIJ821 in Treatment-Resistant Depression

May 23, 2019

Sermonix Pharmaceuticals Adds Three New Members to Its Board of Directors

May 20, 2019

Ayala Pharmaceuticals to Present at ASCO Annual Meeting on Investigational Drug AL101 in Adenoid Cystic Carcinoma and Triple Negative Breast Cancer

May 20, 2019

Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis

May 18, 2019

Talaris Therapeutics, Inc. Announces Promising Phase 2 Data of Novel, Allogeneic Cell Therapy in Living Donor Kidney Transplant Recipients

May 18, 2019

Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development

May 16, 2019

Biothera Pharmaceuticals to Present Clinical Data from Phase 2 Triple Negative Breast Cancer Study at ASCO 2019 Annual Meeting

May 15, 2019

IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win® Immunotherapy in Non-small Cell Lung Cancer

May 15, 2019

Rakuten Medical Highlights Upcoming Presentations and Activities During the ASCO Annual Meeting, May 31 - June 4, 2019 in Chicago

May 13, 2019

Karolinska Development's portfolio company Modus Therapeutics announces results from a Phase 2 study of sevuparin in patients with sickle cell disease

May 10, 2019

Samumed Announces Multiple Presentations at the 19th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

May 9, 2019

Rainier Therapeutics Announces Upcoming Oral and Poster Presentation on Vofatamab at AACR Bladder Cancer Conference

May 9, 2019

Promethera Biosciences Announces First-Dosing in Phase 2a Clinical Study Evaluating World’s First Liver Stem Cell Therapy in Late-Stage NASH Patients

May 8, 2019

Rett Syndrome Association of Australia and Anavex Life Sciences Announce Initiation of the Phase 2 AVATAR Clinical Study in Patients with Rett Syndrome

May 7, 2019

Sensei Biotherapeutics Announces Clinical Trial Collaboration Agreement with AstraZeneca for Two Phase 2 Studies of SNS-301

May 6, 2019

Engage Therapeutics Presents Data from Part 1, Open-label Run-in of StATES Phase 2b Study of Staccato® Alprazolam at 2019 American Academy of Neurology Annual Meeting

May 6, 2019

AMO Pharma Presents Statistical Analysis of Results of Phase 2 Study of AMO-02 in Adolescents with Autism Spectrum Disorder

May 6, 2019

Engage Therapeutics Presents Data from Part 1, Open-label Run-in of StATES Phase 2b Study of Staccato Alprazolam at 2019 American Academy of Neurology Annual Meeting

May 2, 2019

Context Therapeutics and World-Renowned Cancer Center Announce a Phase 2 Trial for Apristor® in Progesterone Receptor Positive Gynecological Cancers

May 2, 2019

Context Therapeutics and World-Renowned Cancer Center Announce a Phase 2 Trial for Apristor in Progesterone Receptor Positive Gynecological Cancers

May 1, 2019

Tetra Discovery Partners Initiates Phase 2 Clinical Trial of BPN14770 in Patients with Early Alzheimer’s Disease

Apr 30, 2019

Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424

Apr 30, 2019

Impel NeuroPharma To Present Data Highlighting Late-Stage Central Nervous System Pipeline At 2019 American Academy Of Neurology Meeting

Apr 30, 2019

3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH

Apr 29, 2019

OMEICOS Therapeutics Announces First-Dosing in Phase 2 Clinical Study Evaluating its Lead Program OMT-28 in Patients with Persistent Atrial Fibrillation

Apr 25, 2019

Rainier Therapeutics Announces Vofatamab Data Accepted for Presentation at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2019

Cavion to Present Results of Phase 2 Essential Tremor Clinical Trial in Platform Presentation at the American Academy of Neurology

Apr 23, 2019

Fulcrum Therapeutics Acquires Global Rights to Losmapimod, a Potential Disease-Modifying Therapy for Facioscapulohumeral Muscular Dystrophy

Apr 23, 2019

Vyome Therapeutics Begins Dosing in Phase 2 Trial of VB-1953 in Moderate to Severe Inflammatory Acne Vulgaris

Apr 22, 2019

Forbius Announces First Patient Dosed in Phase 2a EGFR-Overexpressing Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Specific Anti-EGFR ADC

Apr 15, 2019

Mirum Pharmaceuticals Presents New Data Demonstrating Durable Improvements in Clinical Outcome Measures in Patients with PFIC2 and Alagille Syndrome Treated with Maralixibat

Apr 15, 2019

Promethera Biosciences Presents Updated Phase 2a Results for World’s First Stem Cell Clinical Trial in ACLF at The International Liver Congress™/ EASL 2019

Apr 12, 2019

Cirius Therapeutics Announces Presentation of Interim Data from Phase 2b Clinical Study of MSDC-0602K at The International Liver Congress 2019

Apr 11, 2019

AriBio Co., Ltd. Announces First Patient Dosing in Phase 2 Study of AR1001 for Alzheimer's Disease

Apr 9, 2019

Peloton Therapeutics Announces Completion of Enrollment in Phase 2 Trial of PT2977 for Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

Apr 9, 2019

Frequency Therapeutics Announces Positive Phase 1/2 Data for Drug Candidate for Hearing Restoration

Apr 9, 2019

Cerevel Therapeutics Announces Publication of Phase 2a Study Results in Neurology on Its Most Advanced Investigational Epilepsy Treatment

Apr 3, 2019

Amylyx Pharmaceuticals Announces First Patients Dosed in PEGASUS Phase 2 Trial of AMX0035 in Alzheimer’s Disease and Expansion of the Trial

Apr 2, 2019

Petra Pharma Strengthens Management Team With Recent Leadership Appointments

Mar 29, 2019

Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing

Mar 28, 2019

Velicept Therapeutics Announces Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder (OAB)

Mar 27, 2019

Mirum Pharmaceuticals to Present Phase 2 Clinical Results of Maralixibat in Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis at the International Liver Congress

Mar 27, 2019

Centrexion Therapeutics Announces Publication of Phase 2 Efficacy Data on CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain in Arthritis & Rheumatology

Mar 27, 2019

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer

Mar 27, 2019

Centrexion Therapeutics Announces Publication of Phase 2 Efficacy Data on CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain in Arthritis and Rheumatology

Mar 25, 2019

Spruce Biosciences Achieves Proof of Concept in Phase 2 Study of Tildacerfont in Congenital Adrenal Hyperplasia

Mar 25, 2019

Alkahest Presents Positive Results from Phase 2a Open Label Study of AKST4290 in Treatment-Naïve neovascular AMD at Retina World Congress

Mar 20, 2019

Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma

Mar 20, 2019

Petra Pharma announces licensing agreement with Takeda Pharmaceutical Company

Mar 20, 2019

Syntrix Announces First Patient Cohort Dosed in Phase 2 Study of Desmetramadol in Diabetic Neuropathic Pain

Mar 19, 2019

Rain Therapeutics Announces First Patient Dosed in Phase 2 Trial of Tarloxotinib for the Treatment of Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertion or HER2-Activating Mutations

Mar 18, 2019

Karuna Announces $68 Million Series B Financing

Mar 14, 2019

ImmunogenX Initiates Phase 2 Trial for its Lead Therapeutic and Diagnostic Candidates Latiglutenase and CypCel

Mar 14, 2019

Alkahest to Present Results from Phase 2a Open Label Study of AKST4290 in wet AMD at Retina World Congress

Mar 13, 2019

Engage Therapeutics to Present Phase 2b Open Label Run-in Data from StATES Trial of Staccato Alprazolam at 2019 American Academy of Neurology Annual Meeting

Mar 11, 2019

Anavex Life Sciences Reaches 50% Enrollment Threshold in ANAVEX2-73 Parkinson’s Disease Dementia (PDD) Phase 2 Study Ahead of Schedule

Mar 8, 2019

Spruce Biosciences Announces Presentation of Positive Topline Data from Phase 2 Study of Tildacerfont (SPR001) in Congenital Adrenal Hyperplasia at the 2019 Annual Meeting of the Endocrine Society (ENDO)

Mar 7, 2019

Forbius Announces First Patient Dosed in Phase 2a Squamous Cell Carcinoma of the Head and Neck (SCCHN) Trial of AVID100, a Novel Anti-EGFR ADC

Mar 6, 2019

Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere's Disease clinical trial

Mar 6, 2019

SanBio to Announce the Results of a Phase 2 STEMTRA Trial Regarding the Use of Regenerative Cell Medicine SB623 as a Treatment for TBI at an Annual Scientific Meeting of the American Association of Neurological Surgeons

Feb 26, 2019

Asana BioSciences Strengthens Leadership Team as ASN002 Phase 2b RADIANT Trial in Atopic Dermatitis Advances with a Second Positive DSMB Recommendation

Feb 21, 2019

First Patient Dosed in Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat Pulmonary Arterial Hypertension

Feb 15, 2019

Rainier Therapeutics Presents Data on Vofatamab in Patients with Advanced Urothelial Cell Carcinoma (Bladder Cancer) Previously Treated with Chemotherapy at ASCO GU 2019

Feb 12, 2019

FluGen’s M2SR Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial Against a Highly Mismatched Virus

Feb 4, 2019

Neurana Pharmaceuticals Announces First Patient Enrolled in the "STAR Study," a Phase 2 Dose Ranging Study of Tolperisone in Acute Muscle Spasms of the Back

Jan 31, 2019

Alexion and Caelum Biosciences Announce Collaboration to Develop Targeted Therapy for Light Chain (AL) Amyloidosis

Jan 24, 2019

Abide Therapeutics Appoints Kevin Finney as President and Chief Operating Officer

Jan 23, 2019

Second Genome Doses First Patient In Phase 2 Clinical Study Of SGM-1019 For The Treatment Of Nonalcoholic Steatohepatitis (NASH)

Jan 22, 2019

Rainier Therapeutics Announces Oral Abstract Presentation on Fierce 21 Phase 2 Trial of Vofatamab in Metastatic Urothelial Cell Carcinoma (Bladder Cancer) at the 2019 ASCO Genitourinary Cancers Symposium

Jan 17, 2019

Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism

Jan 17, 2019

Lakewood-Amedex Prepares To Launch A Phase 2 cDFU Clinical Trial for Its Nu-3 Antimicrobial In The Bahamas

Jan 16, 2019

United Neuroscience Announces Positive Top-Line Results from Phase 2a Clinical Study of UB-311 Vaccine in Patients with Alzheimer's Disease

Jan 14, 2019

Sound Pharmaceuticals advances Phase 2 hearing loss clinical trial in Cystic Fibrosis

Jan 7, 2019

Landos Biopharma Announces Final Safety Results from Phase 1 Study of BT-11 in Healthy Volunteers

Jan 7, 2019

F2G Expands Investor Syndicate and Progresses Phase 2b Study for Novel Antifungal

Jan 4, 2019

Aura Biosciences Announces Successful Outcome of End of Phase 2 Meeting with FDA for AU-011 for the Treatment of Patients with Choroidal Melanoma

Jan 4, 2019

BlackThorn Therapeutics Announces R&D Updates

Jan 4, 2019

Tarveda Therapeutics Provides Year-End Update

Jan 4, 2019

BlackThorn Therapeutics Announces RandD Updates

Dec 20, 2018

Apexigen Announces Clinical Collaboration On A New Phase 2 Trial For APX005M In Sarcoma

Dec 20, 2018

Sirnaomics Receives FDA Clearance to Initiate Phase 2 Study of STP705 for the Treatment of Non-Melanoma Skin Cancer

Dec 20, 2018

Xynomic Pharma Acquires Global Exclusive Rights to Phase 2 Ready mTORC1/2 Inhibitor from Boehringer Ingelheim

Dec 20, 2018

Da Volterra Announces Enrollment of First Patients in SHIELD, a Phase 2 Clinical Trial with DAV132, a Novel Microbiota Protective Therapy

Dec 18, 2018

Palladio Biosciences Announces Dosing of First Patients with Lixivaptan in ELiSA, a Phase 2 Clinical Study in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Dec 18, 2018

Aristea Therapeutics Launches with Phase 2 Drug Candidate and $15M in Series A Funding from Novo Holdings A/S

Dec 17, 2018

HOOKIPA Doses First Patient in a Phase 2 Clinical Trial of Prophylactic Vaccine Candidate HB-101 against Cytomegalovirus

Dec 17, 2018

Vedanta Biosciences Initiates Phase 2 Study for Lead Rationally-Defined Bacterial Consortium Product Candidate, VE303

Dec 17, 2018

Ayala Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study of Lead Product Candidate AL101 for Adenoid Cystic Carcinoma with Notch Activated Mutations

Dec 17, 2018

Alkahest Announces Positive Top-Line Data from Two Phase 2a Studies of AKST4290 in Individuals with Wet Age-Related Macular Degeneration

Dec 13, 2018

Adynxx Announces Notice Of Award For $5.7M In Federal Grant Funding

Dec 13, 2018

EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled

Dec 13, 2018

NeuroRx Presents Phase 2 Efficacy & Safety Data for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression

Dec 13, 2018

NeuroRx Presents Phase 2 Efficacy and Safety Data for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression

Dec 11, 2018

KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms

Dec 10, 2018

Karuna Pharmaceuticals to Present Results of KarXT Phase 1 Study at American College of Neuropsychopharmacology Annual Meeting

Dec 10, 2018

Sermonix Announces FDA Acceptance of IND Application; Will Begin Phase 2 Trial of Lasofoxifene for Targeted Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

Dec 4, 2018

Alkahest Doses First Subject in Phase 2 Clinical Trial of GRF6021 in Patients with Parkinson's Disease and Cognitive Impairment

Dec 3, 2018

Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

Dec 3, 2018

Engage Therapeutics Successfully Completes Open Label Portion of Phase 2b StATES Study and Begins Enrollment in Double-Blind Placebo-Controlled Portion

Dec 1, 2018

Tolero Pharmaceuticals Presents Updated Clinical Data from Ongoing Phase 2 Zella 201 Study Evaluating Investigational Agent Alvocidib in Patients with MCL-1 Dependent Relapsed or Refractory AML at ASH 2018

Nov 26, 2018

MicuRx Enrolls First Patient in a Phase 2 Clinical Trial in U.S. for Novel Antibiotic, Contezolid Acefosamil

Nov 16, 2018

AIVITA Biomedical Announces Treatment of First Two Patients in Phase 2 Glioblastoma Trial

Nov 15, 2018

Saniona’s partner Cadent Therapeutics initiates Phase 2 for CAD-1883 and secures USD 40 million financing

Nov 15, 2018

Cadent Therapeutics Secures $40 Million Series B Financing to Advance Pipeline of Novel Therapies for Movement and Cognitive Disorders

Nov 15, 2018

DNAtrix To Present Interim Phase 2 Results of DNX-2401 with Pembrolizumab for Glioblastoma

Nov 15, 2018

Visterra Presents Data Demonstrating Safety, Tolerability and Positive Clinical Activity Trends of VIS410 in Non-Hospitalized Patients with Influenza A

Nov 14, 2018

Attenua Announces First Patient Treated in Phase 2 Clinical Trial in Chronic Cough with Bradanicline

Nov 13, 2018

Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection

Nov 9, 2018

NGM Bio Announces New Histology Data from Phase 2 Trial of NGM282 in Patients with NASH

Nov 8, 2018

Recursion Secures $1.6M NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, a Key Age-Related Disease Process

Nov 8, 2018

Cognition Therapeutics Initiates Patient Dosing in Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer's Disease

Nov 7, 2018

Mirum Pharmaceuticals Secures $120 Million in Series A Financing to Develop Phase 3-Ready Maralixibat for Rare Liver Diseases

Nov 6, 2018

NGM Bio Announces Multiple Presentations at AASLD's The Liver Meeting®, Including New NASH Histology Data from the Phase 2 Trial of NGM282 and Topline Phase 1b Data for NGM313

Nov 6, 2018

Sensei Biotherapeutics Presents Clinical Trial Data Demonstrating SNS-301 Induces Rapid and Robust Antigen-specific Immune Responses at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

Nov 1, 2018

SanBio Announces Phase 2 STEMTRA Trial Using SB623 Cells for Treatment of Patients with Traumatic Brain Injury Met Primary Endpoint

Oct 30, 2018

Alzheimer's Association Awards M3 Biotechnology, Inc. with Part the Cloud to RESCUE Grant to Support Phase 2 Clinical Trials of NDX-1017 to treat Alzheimer's

Oct 30, 2018

First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX2-73 for the Treatment of Parkinson’s Disease Dementia (PDD)

Oct 30, 2018

ImmusanT Initiates Phase 2 Enrollment for its Lead Therapeutic Vaccine Candidate in Patients With Celiac Disease in Australia and New Zealand

Oct 29, 2018

MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta

Oct 25, 2018

AIVITA Biomedical Enrolls First Patient in Phase 2 Glioblastoma Trial

Oct 25, 2018

Cirius Therapeutics Reports Positive Data for MSDC-0602K in Interim Analysis of Phase 2b Clinical Trial in NASH Patients with Fibrosis

Oct 24, 2018

Imara Announces Presentation at the Annual Sickle Cell and Thalassaemia Conference

Oct 24, 2018

Cortexyme Announces Phase 1 Data Demonstrating COR388 is Safe and Well Tolerated in Healthy Older Volunteers and Alzheimer’s Patients

Oct 24, 2018

Oyster Point Announces Positive Results From Two Separate Phase 2b Clinical Trials of the Company’s Investigational Treatments for Dry Eye Disease

Oct 24, 2018

EIP Pharma Announces Clinical Study Presentations at the 11th Clinical Trials on Alzheimer's Disease Conference and Provides Update on Phase 2b Clinical Study Enrollment

Oct 24, 2018

Samumed Phase 2b Trial in Knee Osteoarthritis Meets Primary Endpoints

Oct 24, 2018

Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease

Oct 23, 2018

Context Therapeutics Reports Encouraging Phase 1 Safety and Efficacy Data of Apristor® in Progesterone Receptor Positive Cancers

Oct 23, 2018

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

Oct 23, 2018

Casma Therapeutics Appoints Two Experts in Lysosomal Proteostasis Pathways and Functional Genomics to Scientific Advisory Board

Oct 23, 2018

Epirium Bio Appoints Longitude Capital Senior Investment Professional Cristina Ghenoiu, Ph.D., as Senior Vice President of Research and Development Operations and New Product Planning

Oct 23, 2018

Nurix Therapeutics Closes $120 Million Financing to Advance Targeted Protein Modulation Drug Pipeline

Oct 23, 2018

Viriom Initiates Phase 2 Clinical Study of Elsulfavirine for Treatment of COVID-19

Oct 23, 2018

AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management

Oct 23, 2018

Context Therapeutics Reports Encouraging Phase 1 Safety and Efficacy Data of Apristor in Progesterone Receptor Positive Cancers

Oct 23, 2018

enGene Receives Funding Through Cystic Fibrosis Foundation's Path to a Cure for the Discovery of Novel Gene Therapies to Treat Cystic Fibrosis

Oct 23, 2018

Triplet Therapeutics to Present at Stifel Virtual Healthcare Conference

Oct 23, 2018

Anima Biotech to Present at Multiple Investor and Scientific Conferences in March

Oct 23, 2018

Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform

Oct 23, 2018

Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines

Oct 22, 2018

Forbius Announces First Patient Dosed in Phase 2 Trial of anti-EGFR ADC AVID100 in EGFR-Overexpressing Squamous NSCLC

Oct 22, 2018

Results from Celtaxsys’ Acebilustat Phase 2 Trial in Cystic Fibrosis Patients Showing Clinically Meaningful Improvement in Pulmonary Exacerbations Presented at the North American Cystic Fibrosis Conference  

Oct 22, 2018

AVEO Oncology and EUSA Pharma Announce Updated Interim Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma

Oct 19, 2018

Sensei Biotherapeutics Reports Results from Phase 1 Clinical Trial of SNS-301, a First-in-Class Cancer Immunotherapy Targeting ASPH, a Novel Tumor-Specific Antigen

Oct 16, 2018

eFFECTOR Therapeutics Announces Clinical Collaboration with Merck to Conduct a Phase 2 Combination Trial to Evaluate eFFECTOR's Tomivosertib (eFT508) with KEYTRUDA® (pembrolizumab) for Metastatic Triple Negative Breast Cancer

Oct 16, 2018

Abide Therapeutics Announces Initiation of Phase 2 Clinical Trial of ABX-1431 in Tourette Syndrome

Oct 16, 2018

Velicept Therapeutics Raises an Additional $15 Million in Series B Round, Initiates Phase 2b Study Evaluating Once Daily Dosing of Solabegron in Patients with Overactive Bladder (OAB) and Receives Issuance of Additional U.S. Patent

Oct 16, 2018

Samumed to Present Data from Phase 2b Trial of SM04690 for Treatment of Knee Osteoarthritis at 2018 American College of Rheumatology (ACR) Annual Meeting

Oct 15, 2018

PellePharm Presents Updated Data from Two Phase 2 Studies Demonstrating the Potential of Patidegib Topical Gel to Treat Basal Cell Carcinomas in Patients with Gorlin Syndrome and in Patients with Non-Gorlin Sporadic BCCs

Oct 15, 2018

Karuna Announces First Patient Dosed in Phase 2 Study of Lead Product Candidate KarXT for the Treatment of Schizophrenia

Oct 15, 2018

PolyPid Begins Phase 2 Study to Assess Safety and Efficacy of D-PLEX100 in Prevention of Abdominal Surgical Site Infections

Oct 15, 2018

FluGen Completes Dosing of Phase 2 Study to Assess Effectiveness of Novel Influenza Vaccine Designed to Protect Against Mismatched Strains

Oct 12, 2018

MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD

Oct 11, 2018

Imara Announces Upcoming Presentation at the 46th Annual National Sickle Cell Disease Association of America (SCDAA) Convention

Oct 11, 2018

Data from Celtaxsys’ Acebilustat Phase 2 Trial addressing Lung Inflammation in CF Patients to be presented at the North American Cystic Fibrosis Conference

Oct 10, 2018

Lycera Announces Presentations at the 2018 ESMO Congress for LYC-55716, a First-in-class RORgamma Agonist Candidate

Oct 9, 2018

Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer

Oct 8, 2018

Lyra Therapeutics Presents Clinical Data for LYR-210 for Treatment of Chronic Rhinosinusitis at the American Rhinologic Society Annual Meeting

Oct 5, 2018

Cavion Announces Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study

Oct 4, 2018

Cavion to Announce Results of its Phase 2 Essential Tremor Clinical Trial

Oct 4, 2018

Vedanta Biosciences Announces Successful Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303

Oct 2, 2018

Cognition Therapeutics Receives $16.6 Million Multiyear NIA Grant for Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease

Sep 27, 2018

CytoSen Therapeutics Receives FDA’s Favorable Response to Pre-IND Meeting Package for Phase 2 Study in AML

Sep 27, 2018

ImmusanT Announces First Patient Dosed in Phase 2 Trial of Therapeutic Vaccine for Celiac Disease

Sep 26, 2018

Lyra Therapeutics Announces $29.5 Million Series B Financing to Advance Innovative Therapeutics for Ear, Nose and Throat Diseases

Sep 20, 2018

AIVITA Biomedical Announces Treatment of First Patient in Phase 2 Ovarian Cancer Trial

Sep 19, 2018

Amygdala Neurosciences Announces the $12.4 Million HEAL Initiative Sponsored SEARCH (Safety and Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People with Opioid Use Disorder) Program of Phase 2 Clinical Studies

Sep 12, 2018

Amygdala Neurosciences and NIAAA will Conduct a Phase 2 Clinical study of ANS-6637 for the Treatment of Alcohol Use Disorder

Sep 11, 2018

Andrew Cheng, MD, PhD Joins Akero Therapeutics as President and Chief Executive Officer

Sep 11, 2018

Imara Announces CEO Rahul Ballal, Ph.D., Will Present at the 7th Annual Sickle Cell Disease Therapeutic Conference

Sep 5, 2018

Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

Sep 5, 2018

Thrombolytic Science Initiates Phase 2 Clinical Trial of its Novel Treatment Regimen for Ischemic Stroke

Sep 4, 2018

NeuroRx Announces Phase 2 Data from NRX-101, Initiates Pivotal Study for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB)

Aug 29, 2018

KaNDy Therapeutics Successfully Raises £25 Million in a Series C Financing

Aug 8, 2018

Apexigen Raises $73 Million In Series B And Series C Financings

Aug 7, 2018

Sanifit Announces Completion of Enrollment in CaLIPSO - its Phase 2b Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialysis

Aug 2, 2018

Karuna Completes $42 Million Series A Financing Round to Advance Selective Muscarinic Receptor Agonist Program into Phase 2 Study

Aug 2, 2018

Avelas Biosciences Initiates Period 2 of Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Aug 2, 2018

Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients

Aug 2, 2018

Bonti Announces Successful Completion of Phase 2a Scar Reduction Clinical Study

Jul 25, 2018

Qu Biologics enrolls the first patient in new Phase 2 Crohn’s Disease clinical trial

Jul 23, 2018

Tolero Pharmaceuticals Advances Investigational Agent Alvocidib into Second Stage of Phase 2 Zella 201 Study in Patients with Relapsed Refractory MCL-1-Dependent AML

Jul 19, 2018

Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 2 Trial of Peptelligence-Engineered Oral KORSUVA™

Jul 19, 2018

Asana BioSciences Initiates Phase 2b Study of ASN002 in Patients with Moderate-to-Severe Atopic Dermatitis (RADIANT)

Jul 17, 2018

OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation

Jul 17, 2018

Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations

Jul 16, 2018

Concentric Analgesics Initiates Phase 2 Clinical Study of CA-008 for the Treatment of Post-Surgical Pain

Jul 12, 2018

Oyster Point Pharma Announces Positive Results from Phase 2 Clinical Trial of the Company’s Investigational Treatment for Dry Eye Disease

Jul 11, 2018

BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia

Jul 11, 2018

BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia Israel - English USA - English

Jul 10, 2018

Tetra Discovery Partners Initiates Phase 2 Trial of BPN14770 in Fragile X Syndrome

Jul 10, 2018

Vidac Pharma Announces Initiation of Phase 2b Clinical Trial of VDA-1102 Ointment in Patients with Actinic Keratosis

Jul 9, 2018

Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX2-73 for the Treatment of Parkinson’s Disease Dementia

Jun 28, 2018

BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury

Jun 26, 2018

Enteris BioPharma Announces Positive Results from Expanded Phase 2a Clinical Trial of Ovarest (oral leuprolide tablet) for Endometriosis

Jun 19, 2018

Karuna Receives $8 Million Wellcome Trust Award to Advance First-in-Class Phase 2 Clinical Program in Schizophrenia

Jun 19, 2018

Leading BioSciences Reports Positive Interim Results from Phase 2 Trial of LB1148 in Patients Undergoing Major Surgery

Jun 6, 2018

Peloton Therapeutics Initiates Phase 2 Trial of Oral HIF-2α Inhibitor PT2977 for Treatment of von Hippel-Lindau Disease-associated Kidney Cancer

Jun 4, 2018

Tarveda Therapeutics Announces Results from Phase 1 Study of PEN-221 Presented at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2018

First Patient Dosed in the Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat a Rare and Severe Form of Kidney Disease, Focal Segmental Glomerulosclerosis

May 30, 2018

NanOlogy™ Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer

May 30, 2018

Lycera to Present on First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 ASCO Annual Meeting

May 30, 2018

NanOlogy™ Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac for Treatment of Prostate Cancer

May 29, 2018

Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)

May 24, 2018

Tarveda Therapeutics Announces Dosing of First Patient in Phase 1/2a Study of PEN-866 for Patients with Solid Malignancies

May 19, 2018

Centrexion Therapeutics Announces CNTX-4975 and CNTX-6970 Clinical Data Presentations at the 34th Annual American Academy of Pain Medicine Meeting

May 18, 2018

Qu Biologics Begins Phase 2 Clinical Trial in Crohn’s Disease

May 17, 2018

Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July

May 16, 2018

Iconic Therapeutics Initiates Second Phase 2 Study of ICON-1 in Patients With Neovascular (wet) AMD

May 14, 2018

Complexa Appoints Francisco D. Salva Chief Executive Officer and President

May 10, 2018

Knopp Biosciences Announces Publication of Phase 2 Trial Results of dexpramipexole in Hypereosinophilic Syndromes (HES) in Blood

May 9, 2018

Bonti Announces Start of LANTERN-2 Phase 2 Clinical Trial Evaluating EB-001T in Treating Focal Muscle Pain

May 8, 2018

Palladio Biosciences Receives FDA IND Clearance to Begin the ELISA Study, a Phase 2 Clinical Trial with Lixivaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

May 8, 2018

Data from Spyryx Biosciences' HOPE-1 Phase 2 Clinical Trial to be Presented in a Late-Breaking Oral Presentation at the 41st European Cystic Fibrosis Conference

May 4, 2018

Amylyx Pharmaceuticals Announces First Patients Enroll in Open Label Extension of CENTAUR Phase 2 Clinical Trial of AMX0035 for Treatment of Amyotrophic Lateral Sclerosis

May 3, 2018

Engage Therapeutics Doses First Patient in Phase 2b Trial of Epilepsy Seizure Rescue Therapy Staccato® Alprazolam

May 3, 2018

Engage Therapeutics Doses First Patient in Phase 2b Trial of Epilepsy Seizure Rescue Therapy Staccato Alprazolam

May 2, 2018

Cirius Therapeutics Reaches Enrollment Target in Phase 2b EMMINENCE Trial in NASH

Apr 30, 2018

Enteris BioPharma Announces Completion of Recruitment in Expanded Phase 2a Clinical Trial of Ovarest (oral leuprolide tablet) for Endometriosis

Apr 26, 2018

Neuraltus Pharmaceuticals Reports Results from Phase 2 NP001 Study in Amyotrophic Lateral Sclerosis (ALS)

Apr 25, 2018

Alkahest Announces Initiation of Phase 2 Clinical Trial of GRF6019 in Alzheimer's Disease

Apr 24, 2018

Rebiotix Presents Posters at ECCMID 2018 Highlighting Microbiome Health Index™ Value Potential and RBX2660 Phase 2 Clinical Program Data

Apr 23, 2018

AOBiome Therapeutics Expands Clinical-Stage Pipeline, Initiates Phase 2 Clinical Trial for Episodic Migraine

Apr 18, 2018

Tetherex Pharmaceuticals, Inc. Completes $50M Series B Financing

Apr 14, 2018

NGM Bio Announces Results From Phase 2 Study Of NGM282 In NASH Patients Demonstrating Clinically Significant Improvements In Liver Histology After 12 Weeks

Apr 12, 2018

Adynxx Announces Results of the ADYX-004 Phase 2 Study of Brivoligide (AYX1) for the Treatment of Post-Surgical Pain

Apr 9, 2018

Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018

Apr 5, 2018

Lycera to Present Clinical Results and Supporting Preclinical Data for First-In-Class RORgamma Agonist LYC-55716 at the 2018 AACR Annual Meeting

Mar 28, 2018

Biscayne Neurotherapeutics Licenses Chinese Rights To Its Novel Antiepileptic Agent To Global Drug Development Centre (GDCC) China

Mar 26, 2018

Allecra Therapeutics Announces Positive Top-Line Results from Phase 2 CACTUS Study of its Lead Candidate, AAI101, in Combination with Cefepime to Treat Complicated Urinary Tract Infections (cUTI)

Mar 26, 2018

Lutris Pharma Doses First U.S. Patients in Phase 2 Trial of LUT014 -- a Topical Gel for the Reduction of Dose-Limiting Acneiform Lesions -- in Metastatic Colorectal Cancer Patients Treated with EGFR Inhibitor Therapy

Mar 21, 2018

Amazentis SA Announces Completion of Series C Financing

Mar 20, 2018

First Patient Enrolled in Cavion Multi-Center Phase 2 Clinical Trial in Epilepsy

Mar 19, 2018

Velicept Therapeutics Initiates First of Two Phase 2b Dose-Ranging Studies of Solabegron in Patients with Overactive Bladder (OAB); Finalizes Novel, Once Daily Formulation; and Receives U.S. Patent Covering OAB

Mar 15, 2018

Tetra Discovery Partners Announces FDA Clearance of IND for Phase 2 Trial of BPN14770 in Fragile X Syndrome

Mar 15, 2018

AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1

Mar 12, 2018

NGM Bio Announces Publication In The Lancet Of Phase 2 Study Of NGM282 In NASH Patients And Upcoming Presentations Of NGM282 NASH Histology Data And NGM282 PSC Data At The International Liver Congress 2018

Mar 12, 2018

Frequency Therapeutics Welcomes Former Otonomy CSO as Executive Vice President of Clinical Development

Mar 7, 2018

EIP Pharma Announces Publication of Positive Alzheimer's Disease Clinical Study Data with Neflamapimod

Mar 1, 2018

Finch Therapeutics Group Raises $36 Million in Series B Financing

Feb 19, 2018

sterna biologicals Reports Phase 2a Study Data Demonstrating Efficacy of Its GATA-3 Specific DNAzyme Formulation SB012 in Patients with Ulcerative Colitis

Feb 16, 2018

Avillion Advances Co-development Programme with Merck: IND Now Open for Phase 2 Study of M1095, an Anti-IL-17 A/F Nanobody in Psoriasis

Feb 14, 2018

IRX Therapeutics Announces Initiation of Phase 2 Clinical Trial of IRX-2 in Squamous Cervical or Vulvar Intraepithelial Neoplasia 3

Feb 13, 2018

Imara Doses First Patient in Phase 2a Clinical Trial of IMR-687 for Sickle Cell Disease

Feb 13, 2018

Nohla Therapeutics Initiates Global LAUNCH Phase 2 Trial of NLA101 in Patients with AML

Feb 8, 2018

Bonti Announces Dosing of the First Patient in the SHINE-1 Phase 2 Clinical Study Evaluating EB-001 for Scar Reduction

Feb 8, 2018

ArmaGen's AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS I

Feb 7, 2018

Xcovery Announces Initiation of Phase 2 Clinical Trial for Ensartinib in Melanoma Patients with ALK Alternations

Feb 7, 2018

Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis

Feb 6, 2018

Biothera Pharmaceuticals Commences Phase 2 Head and Neck Cancer Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA (pembrolizumab)

Jan 16, 2018

Context Therapeutics Announces the Acquisition of Apristor™ (Onapristone XR), an Investigational Phase 2 Drug for Metastatic Breast Cancer

Jan 9, 2018

Rebiotix Highlights 2017 Achievements and 2018 Objectives

Jan 9, 2018

Emotional Brain's FSIAD Products Lybrido and Lybridos show High Efficacy and Safety in Phase 2B Trials USA - English USA - English

Jan 8, 2018

Novaliq Announces First Patient Enrolled in Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Dry Eye Disease

Jan 5, 2018

KBP Biosciences Raises $76 Million in Series A Financing and Appoints Brian P. McVeigh as Chief Executive Officer

Jan 4, 2018

Lycera Announces Initiation of Phase 1b Study of Novel Immuno-Oncology Candidate LYC-55716 in Combination with Pembrolizumab

Jan 4, 2018

Avelas Biosciences Completes Period 1 Patient Enrollment in Phase 2 Study of AVB-620 in Women with Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Jan 4, 2018

Neuraltus Pharmaceuticals Announces Completion of Last Patient Visit in Confirmatory Phase 2 Study of NP001 for the Treatment of Amyotrophic Lateral Sclerosis

Jan 4, 2018

ImmusanT Provides Year-End Update and Outlines Goals for 2018

Jan 3, 2018

Tarveda Therapeutics Provides Year-End Update and Outlines Milestones for 2018

Jan 3, 2018

Enteris BioPharma Announces Positive Results from Phase 2a Clinical Trial of Ovarest (oral leuprolide tablet) for Endometriosis

Jan 2, 2018

NanOlogy™ to Present Update on Cancer Treatment Clinical Program at Biotech Showcase in San Francisco

Dec 18, 2017

NanOlogy™ Announces First Patient Enrolled in a Pancreatic Cancer Phase 2 Clinical Trial of NanoPac® Adding to Trials in Prostate and Ovarian Cancers

Dec 18, 2017

NanOlogy™ Announces First Patient Enrolled in a Pancreatic Cancer Phase 2 Clinical Trial of NanoPac Adding to Trials in Prostate and Ovarian Cancers

Dec 11, 2017

Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials

Dec 7, 2017

BlackThorn Therapeutics Presents Preclinical and Clinical Data From Its First-in-Class NOPR Antagonist at American College of Neuropsychopharmacology Annual Meeting

Dec 4, 2017

Atox Bio Closes $30 Million Investment

Nov 28, 2017

ImmusanT Data Shows Up-dosing Substantially Increases Nexvax2 Dose Levels That Are Safe and Tolerable, Further Supports Phase 2 Studies

Nov 16, 2017

Khondrion Will Present First Results of KHENERGY Study France - Français USA - English España - español Deutschland - Deutsch

Nov 7, 2017

NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Mucinous Cysts of the Pancreas

Nov 7, 2017

Lycera Presents Tumor Selection Rationale for Phase 2a Study at Society for Immunotherapy of Cancer's (SITC) 2017 Annual Meeting for RORgamma Agonist, LYC-55716

Nov 7, 2017

OrthoTrophix Presents the Key Data of the TPX-100 Phase 2 Study as a Late Breaking Abstract at American College of Rheumatology Annual Meeting

Nov 7, 2017

OncoQuest Announces Presentation of Translational Immunology Data from Phase 2 Clinical Study Examining Oregovomab in Combination with Chemotherapy in Front Line Ovarian Cancer at the International Meeting of European Society of Gynaecological Oncology (ESGO) 2017

Nov 7, 2017

NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac for Treatment of Mucinous Cysts of the Pancreas

Nov 7, 2017

Pique Therapeutics Announces Positive Results in Phase 2 Clinical Trial of Lead Immunotherapy for Non-Small Cell Lung Cancer

Nov 6, 2017

Samumed Announces Results of Phase 2 Trial of SM04690 Demonstrating Evidence of Cartilage Regeneration in Patients with Knee Osteoarthritis

Nov 1, 2017

University of Oxford and Sound Pharmaceuticals begin Phase 2 clinical trial on novel treatment for bipolar disorder

Nov 1, 2017

FDA Grants Fast Track Designation to Visterra’s VIS410 for Treatment of Hospitalized Patients with Influenza A

Nov 1, 2017

Quark Pharmaceuticals, Inc. Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting

Nov 1, 2017

United Neuroscience Presents Data for Phase 2 Active Vaccine Program UB-311 at the Clinical Trials on Alzheimer's Disease 2017 Meeting

Oct 26, 2017

Neurana Pharmaceuticals Reports Successful Results in Study Designed to Confirm the Non-Sedative Effects of Tolperisone, a Novel Skeletal Muscle Relaxant

Oct 24, 2017

Samumed Announces 52-week Phase 2 Osteoarthritis Data Supporting the Potential of SM04690 as a Disease Modifying Drug

Oct 19, 2017

Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716 RORgamma Agonist into Phase 2a

Oct 19, 2017

AOBiome Therapeutics Reports Positive Efficacy Results from Phase 2b Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne Vulgaris

Oct 18, 2017

Spyryx Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of SPX-101 for the Treatment of Cystic Fibrosis

Oct 16, 2017

New Clinical Data and Microbiome Research from Rebiotix's Phase 2 Program for RBX2660 Highlighted at the World Congress of Gastroenterology at ACG2017

Oct 16, 2017

NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer

Oct 16, 2017

NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac for Treatment of Prostate Cancer

Oct 13, 2017

BioAegis Therapeutics Hires Dr. Mark J. DiNubile as Chief Medical Officer to Spearhead Forthcoming Phase 2 Clinical Trials in Community-Acquired Pneumonia

Oct 12, 2017

Vidac Pharma Reports Positive Results from Phase 2a Proof-of-Concept Trial of VDA-1102 Ointment in Actinic Keratosis

Oct 11, 2017

Izun Pharmaceuticals Announces Positive Results from Phase 2 Double Blind Oral Mucositis Trial

Oct 9, 2017

NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Ovarian Cancer

Oct 9, 2017

NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac for Ovarian Cancer

Oct 4, 2017

Adynxx Completes Enrollment in ADYX-004, a Phase 2 Study of Brivoligide (AYX1), Lead Compound for the Treatment of Post-Surgical Pain

Oct 4, 2017

eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer

Oct 4, 2017

Presentations at ID Week™ 2017 Highlight Clinical Results and Microbiome Analysis of Patients Treated in Rebiotix's RBX2660 Phase 2 Studies

Oct 3, 2017

Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Meniere's Disease

Sep 27, 2017

Engage Therapeutics Announces $23 Million Series A Financing to Advance Phase 2b Development of Novel Epileptic Seizure Rescue Therapy

Sep 26, 2017

Centrexion Therapeutics to Present Clinical Data from Pipeline of Chronic Pain Treatments at the 11th Annual Pain and Migraine Therapeutics Summit

Sep 26, 2017

Neurana Pharmaceuticals Completes Enrollment in Study Designed to Confirm the Non-Sedative Effects of Tolperisone, a Novel Skeletal Muscle Relaxant

Sep 21, 2017

Patara Pharma's Phase 2 Study Results for Treatment of Persistent Cough in IPF Patients Published in The Lancet Respiratory Medicine

Sep 20, 2017

Cavion Announces First Patient Enrolled in Its Multi-Center Phase 2 Clinical Trial in Essential Tremor

Sep 20, 2017

AOBiome Expands Intellectual Property Estate, Announces Issuance of U.S. Patent for Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne

Sep 11, 2017

Symphogen A/S: Symphogen presents detailed results for randomized Phase 2 study with Sym004 in refractory metastatic colorectal cancer at ESMO 2017 Congress

Sep 11, 2017

IRX Therapeutics Presents Positive IRX-2 Phase 2a Head and Neck Squamous Cell Carcinoma Clinical Results at the European Society for Medical Oncology Annual Congress 2017

Sep 6, 2017

Longeveron Initiates Phase 2b Stem Cell Therapy Trial to Treat Aging Frailty

Sep 5, 2017

ReViral initiates Phase 2a study of RV521 for treatment of Respiratory Syncytial Virus

Aug 31, 2017

Symphogen Presents Promising Results From a Randomized Phase 2 Study With Sym004 at ESMO 2017 Congress

Aug 31, 2017

Symphogen A/S: Symphogen presents promising results from a randomized Phase 2 study with Sym004 at ESMO 2017 Congress

Aug 28, 2017

Gliknik Announces Dosing Of First Patient In Phase 2 Trial Targeting Prevention Of Recurrence Of High-Risk Oral Cavity Cancer

Aug 24, 2017

Enteris BioPharma Doses First Woman in Phase 2a Clinical Trial of Ovarest™ (oral leuprolide tablet) for Endometriosis

Aug 23, 2017

Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Osteoarthritis

Aug 23, 2017

Bonti Announces Start of LANTERN-1 Phase 2 Clinical Study Evaluating EB-001 in Reducing Musculoskeletal Pain

Aug 9, 2017

Allegro Ophthalmics Announces Positive Topline Results from DEL MAR Phase 2b Stage 2 Trial Evaluating Luminate in Patients with Diabetic Macular Edema

Aug 9, 2017

Bonti Announces Topline Results of EB-001 Phase 2A Clinical Study in Glabellar Lines

Aug 7, 2017

Rebiotix Announces First Patient Enrolled in Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection

Aug 3, 2017

Avelas Biosciences Doses First Patient in Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Aug 2, 2017

Oxeia Biopharmaceuticals Announces Clinical Advancement Of Concussion Treatment

Aug 2, 2017

IRX Therapeutics to Present IRX-2 Clinical and Biomarker Updates at Upcoming Medical Conferences

Jul 31, 2017

PellePharm Announces Topline Results from Phase 2 Study of Topical Patidegib in Gorlin Syndrome Basal Cell Carcinomas and Third Closing of a $20 Million Series B Financing

Jul 27, 2017

Samumed Successfully Completed 52-Week Phase 2 Study for Treatment of Osteoarthritis of the Knee

Jul 27, 2017

Quark Pharmaceuticals RNAi Drug Succeeds in Phase 2 Study to Prevent Acute Kidney Injury Following Cardiac Surgery

Jul 26, 2017

Neurana Pharmaceuticals Initiates Study to Assess the Non-Sedating Properties of Tolperisone Among Healthy Volunteers

Jul 26, 2017

Complexa Raises $62 Million in Series C Financing to Test CXA-10 in Two Orphan Disease Proof-of-Concept Trials

Jul 24, 2017

BlackThorn Therapeutics Enrolls First Patient in Phase 2a Study of Lead Compound, BTRX-246040, in Major Depressive Disorder

Jul 20, 2017

Centrexion Therapeutics to Present Phase 2b Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma at the American Podiatric Medical Association 2017 Annual Scientific Meeting

Jul 19, 2017

Imago BioSciences Doses First Patients in the Phase 2a Portion of the Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Jul 18, 2017

Centrexion Therapeutics Provides Updates and Advancements for Pipeline of Chronic Pain Treatments

Jul 17, 2017

Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer

Jun 20, 2017

Spyryx Biosciences Expands Development Award with Cystic Fibrosis Foundation; Presents Phase 1 Data for SPX-101 at the European Cystic Fibrosis Conference

Jun 13, 2017

Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain

May 30, 2017

Asana BioSciences Initiates Phase 2 Evaluation of ASN002, a Novel SYK/JAK Inhibitor, in NHL, CLL and MF

May 25, 2017

Neurana Pharmaceuticals Receives Notice of Allowance of Patents For Tolperisone, a Novel Skeletal Muscle Relaxant

May 24, 2017

Spyryx Biosciences Reports Positive Data on SPX-101 at American Thoracic Society International Conference

May 17, 2017

Celtaxsys announces full enrollment of its landmark EMPIRE-CF phase 2b clinical trial assessing the potential of novel anti-inflammatory investigational therapy, oral acebilustat, to preserve lung function in CF patients

May 11, 2017

Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia

May 11, 2017

Peloton Therapeutics Initiates Patient Dosing in Phase 2 Study of PT2385 for von Hippel-Lindau Disease-Associated Kidney Cancer

May 5, 2017

Spyryx Biosciences Partners with Cystic Fibrosis Canada, Serves as Presenting Sponsor of the 16th Broken Arrow Conference May 4-6, Toronto, Ontario

May 4, 2017

Rebiotix's Phase 3 ready RBX2660 to be Featured in Multiple Sessions at Digestive Disease Week 2017

May 3, 2017

Bonti Announces Hot Topics Presentation of Phase 2a Interim Clinical Data at The Aesthetic Meeting 2017

May 1, 2017

Cantex Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Development for CX-02 in Recurrent Glioblastoma

Apr 27, 2017

Bonti Announces Inaugural Presentation of Phase 2a Clinical Data for Its Lead Product EB-001

Apr 24, 2017

ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers

Apr 22, 2017

NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

Apr 18, 2017

Bonti Raises $11.7 Million in an Oversubscribed Series B Financing to Advance Development of Lead Product EB-001

Apr 13, 2017

AOBiome Completes Patient Enrollment In Phase 2 Clinical Trial Of Lead Candidate B244 To Treat Elevated Blood Pressure

Apr 12, 2017

Milestone Pharmaceuticals to Present Etripamil Phase 2 Data at the Heart Rhythm Society's 38th Annual Scientific Sessions

Apr 11, 2017

Rebiotix Reports Positive Top Line Data from Open-Label Phase 2 Trial of RBX2660 in Recurrent Clostridium difficile

Apr 11, 2017

Cirius Therapeutics Completes $40 Million Series A Financing to Fund Phase 2b Study of MSDC-0602K in NASH, Adds to Executive Team

Apr 3, 2017

AIVITA Biomedical CEO Hans Keirstead, Ph.D. to Present as Distinguished Speaker at Upcoming Stem Cell Summit 2017

Mar 24, 2017

Biothera Pharmaceuticals’ Phase 2 Study of Imprime PGG Combination Therapy in Non-Small Cell Lung Cancer Patients Published in Investigational New Drugs

Mar 16, 2017

Centrexion Therapeutics to Present Late-Breaking Poster at the 33rd Annual American Academy of Pain Medicine Meeting

Mar 7, 2017

Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliveto as Chief Executive Officer

Mar 6, 2017

Samumed Presented Data on Increases in Hair Follicles Observed in Its Phase 2 Biopsy Study for a Potential Treatment of Androgenetic Alopecia (AGA) at Annual Meeting of the American Academy of Dermatology (AAD)

Mar 6, 2017

Castle Creek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for Diacerein 1% Ointment in Treatment of Epidermolysis Bullosa Simplex

Mar 1, 2017

Adynxx Initiates ADYX-004, a Phase 2 Study of AYX1, Lead Compound for the Treatment of Post-Surgical Pain

Feb 24, 2017

Biothera Pharmaceuticals Announces Presentation of Clinical Data Supporting Use of a Patient Selection Biomarker for its Phase 2 Cancer Immunotherapy

Feb 23, 2017

Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA (pembrolizumab)

Feb 22, 2017

ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2 for the Treatment of Celiac Disease

Feb 9, 2017

Iconic Therapeutics to Present Phase 2a EMERGE Trial Results at Miami Meeting

Feb 8, 2017

Neuraltus Pharmaceuticals Provides Enrollment Update on Confirmatory Phase 2 Study of NP001 in ALS

Feb 7, 2017

ArmaGen Announces Oral Presentation of Preliminary Results from its Phase 2 Clinical Trial of AGT-181 in Patients with MPS 1 to be Presented at WORLDSymposium 2017

Feb 6, 2017

Spyryx Biosciences Announces Successful Completion of Phase 1 Clinical Trial for SPX-101 and Planned Phase 2 Initiation in Cystic Fibrosis During 2017

Jan 11, 2017

Bird Rock Bio Receives Approval to Start First in Human Clinical Trial for Namacizumab, Enters Into Agreement with GE Healthcare for Process Development and Scale-up to Provide Clinical Phase 2 cGMP Material, and Enters into a Collaboration and Option Agreement with Janssen Pharmaceuticals, Inc.

Jan 11, 2017

Visterra Doses First Patient in Phase 2a Trial for VIS410, its Monoclonal Antibody in Development for the Treatment of Hospitalized Patients with Influenza A

Jan 10, 2017

Adynxx Announces Closing of Series B Financing

Jan 5, 2017

BlackThorn Therapeutics Secures $14 Million in Series A Extension Financing

Jan 5, 2017

Novaliq Announces Positive Topline Results of Phase 2 Clinical Trial Evaluating CyclASol in Adults with Moderate to Severe Dry Eye Disease

Jan 3, 2017

Bird Rock Bio Receives Approval from ANVISA and CONEP to Initiate the First Phase 2 Study in Brazil of Gerilimzumab for Rheumatoid Arthritis

Dec 16, 2016

AOBiome Launches Phase 2 Clinical Trial Using Novel Bacterial Platform for Treatment of Hypertension

Dec 15, 2016

Karuna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimer's

Dec 13, 2016

Centrexion Therapeutics Announces Highly Statistically Significant Topline Results from Phase 2b Study of CNTX-4975 in Patients with Knee Osteoarthritis Pain

Dec 13, 2016

Innocrin Pharmaceuticals Presents Data from the Ongoing Phase 2 Trial of Seviteronel in Estrogen Receptor-positive or Triple-negative Breast Cancer (CLARITY-01) at the San Antonio Breast Cancer Symposium

Dec 8, 2016

PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome

Dec 8, 2016

EIP Pharma announces positive results with neflamapimod (VX-745) in two Phase 2a clinical trials in patients with Early Alzheimer's Disease

Dec 7, 2016

Lycera Announces Initiation of Phase 2 UPRISE Clinical Trial of LYC-30937-EC for Patients with Moderate Psoriasis

Dec 6, 2016

ENYO Pharma Receives a €2.5 Million Grant from EU under the Horizon2020/SME Instrument Phase 2 Programme for Its Project MIMESIS

Dec 5, 2016

Biothera Pharmaceuticals and Merck Further Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck Cancer

Dec 2, 2016

Promedior Announces Completion of Patient Enrollment Milestones in Phase 2 Clinical Studies of PRM-151 in Both Idiopathic Pulmonary Fibrosis and Myelofibrosis

Nov 30, 2016

Viracta acquires Phase 2 epigenetic drug candidate from Chroma Therapeutics

Nov 29, 2016

Biothera Pharmaceuticals Announces Data Demonstrating Unique Immune Response Profile Generated by Phase 2 Cancer Immunotherapy Imprime PGG

Nov 29, 2016

OncoQuest Announces Positive Interim Results from Its Phase 2b Clinical Study

Nov 22, 2016

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First-Line Therapy in Patients with Endometrial or Squamous Lung Cancer

Nov 16, 2016

EIP Pharma announces upcoming oral presentations of Phase 2a clinical trial results with neflamapimod (VX-745) at Clinical Trials in Alzheimer's Disease (CTAD) conference Dec 8-10, 2016

Nov 11, 2016

Biothera Pharmaceuticals Preclinical Data Further Validate Mechanism of Its Phase 2 Cancer Immunotherapy, Imprime PGG

Nov 8, 2016

Hallux Announces Start of Phase 2 Clinical Trial

Nov 1, 2016

DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA

Nov 1, 2016

ADDING and REPLACING Castle Creek Pharmaceuticals Continues to Build Executive Team as Company Secures Funding, Positive Phase 2 Results

Oct 17, 2016

Data from Rebiotix's Phase 2b Trial of Lead Microbiota-Based Drug Candidate, RBX2660, to be Featured in Late-Breaking Oral Presentation at UEG Week 2016

Oct 13, 2016

Trevi Therapeutics Announces Positive Results from Phase 2 Trial in Prurigo Nodularis

Oct 13, 2016

Allegro Ophthalmics Announces Positive Topline Results from DEL MAR Phase 2b Trial Evaluating Luminate in Patients with Diabetic Macular Edema

Oct 5, 2016

Innocrin Pharmaceuticals, Inc. Appoints Edwina Baskin-Bey, MD as Chief Medical Officer and Expands the Ongoing Phase 2 Study of Seviteronel in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer (TNBC)

Oct 3, 2016

Allegro Ophthalmics Announces Last Patient Enrolled in PACIFIC Phase 2b Clinical Trial of Luminate for Non-Proliferative Diabetic Retinopathy

Sep 22, 2016

Neuraltus Pharmaceuticals Initiates Confirmatory Phase 2 Study of NP001 in Patients with Amyotrophic Lateral Sclerosis

Sep 20, 2016

AOBiome Announces First-of-its Kind Trial of Live Topical Bacterial Treatment for Acne

Sep 19, 2016

Enteris BioPharma's "Feasibility to Licensing" Partner, Cara Therapeutics, Advances Peptelligence™-Engineered CR845 into Phase 2b Clinical Trial in Chronic Pain

Sep 15, 2016

Interim results from Trek Therapeutics' Phase 2 study show triple combination therapy achieves 100% SVR4 in genotype 4 HCV patients

Sep 7, 2016

Leading BioSciences Receives FDA Clearance to Proceed with Phase 2 Clinical Trial of LB1148 for Ileus and Adhesions

Sep 7, 2016

Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis

Aug 24, 2016

Visterra to Present New Clinical Results of VIS410 at the Options IX for the Control of Influenza Conference

Aug 22, 2016

Lycera Announces Initiation of Phase 2 Clinical Trial of LYC-30937-EC in Patients with Ulcerative Colitis

Jun 29, 2016

Vidac Pharma Completes $9 Million Series A Financing

Jun 21, 2016

Trek Therapeutics Initiates Phase 2a Study of Faldaprevir and TD-6450, With and Without Ribavirin, in Patients with HCV GT 1b.

Jun 15, 2016

Allecra Therapeutics Announces €22 Million Series B Financing

May 12, 2016

Innocrin Pharmaceuticals, Inc. Begins Phase 2 Study of Seviteronel in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer and Expands Two Phase 2 Studies of Seviteronel in Men with Metastatic Castrate-resistant Prostate Cancer

May 11, 2016

Braeburn Pharmaceuticals and Camurus announce positive top line results from Phase 2 opioid challenge study with CAM2038 in subjects with opioid use disorder

May 11, 2016

Camurus AB: Braeburn Pharmaceuticals and Camurus Announce Positive Results from Phase 2 Opioid Challenge Study with CAM2038 in Subjects with Opioid Use Disorder

May 11, 2016

Braeburn Pharmaceuticals and Camurus announce positive results from Phase 2 opioid challenge study with CAM2038 in subjects with opioid use disorder

May 6, 2016

Novaliq Announces Last Patient Enrolled in Phase 2 Clinical Trial of CyclASol for the Treatment of Moderate to Severe Dry Eye Disease

Apr 4, 2016

Neuraltus Pharmaceuticals Announces Plans for Second Phase 2 Study of NP001 in ALS Using Biomarker for Enriched Patient Selection

Apr 4, 2016

Biomarker Analyses of Neuraltus Pharmaceuticals' NP001 Phase 2 Data Demonstrate Potential for Treating ALS Patients with Systemic Inflammation

Mar 31, 2016

ArmaGen Announces Initiation of Phase 2 Proof-of-Concept Clinical Trial in Brazil to Study AGT-181 for the Treatment of Hurler Syndrome

Mar 7, 2016

Samumed Presents At The Annual Meeting Of The American Academy Of Dermatology (AAD) Safety And Efficacy Results From Its Phase 2 Androgenetic Alopecia (AGA) Trial

Feb 22, 2016

Camurus AB: Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain

Feb 22, 2016

Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain

Feb 16, 2016

Novaliq Begins Phase 2 Clinical Trial of CyclASol for the Treatment of Moderate to Severe Dry Eye Disease

Jan 25, 2016

Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia

Jan 7, 2016

RDD Pharma Announces Additional Positive Results in a Double-Blind Placebo-Controlled Phase 2a Study in Fecal Incontinence

Jan 5, 2016

Allegro Ophthalmics Announces Last Patient Enrolled in DEL MAR Phase 2b Clinical Trial of Luminate for the Treatment of Diabetic Macular Edema

Dec 23, 2015

Qu Biologics Closes Oversubscribed Financing; Crohn's Disease Phase 2 Clinical Trial Results in First Quarter 2016

Dec 21, 2015

SanBio and Sunovion Begin Patient Recruitment for Phase 2b Trial to Test Regenerative Treatment for Chronic Stroke in North America

Dec 10, 2015

Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting

Nov 18, 2015

Rebiotix Completes Enrollment in Phase 2 Trial of a Microbiota Restoration Therapy (MRT) for the Treatment of Recurrent Clostridium difficile Infection

Nov 3, 2015

MicuRx Reports Positive Top-Line Results From Phase 2 US Clinical Trial For Novel Antibiotic MRX-I

Oct 16, 2015

RDD Pharma Announces Positive Results in a Double-Blind Placebo-Controlled Crossover Phase 2a Study in Fecal Incontinence in Patients with Spinal Cord Injury

Oct 13, 2015

Izun Pharmaceuticals Announces Positive Results from Phase 2 Randomized Trial in Diabetic Foot Ulcers

Oct 8, 2015

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Oct 5, 2015

Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study

Oct 1, 2015

Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer

Sep 22, 2015

Rhizen Pharmaceuticals S.A. announces initiation of Phase 2 study of RV1001 in dogs with T- or B-cell Lymphoma

Sep 8, 2015

Promedior Announces Initiation of a Phase 2 Clinical Study of PRM-151 in Idiopathic Pulmonary Fibrosis (IPF)

Aug 31, 2015

MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections

Aug 20, 2015

Enteris BioPharma's Formulation Technology Enables Oral Delivery of Cara Therapeutics' CR845 Peptide in Phase 2 Trial in Osteoarthritis

Jul 28, 2015

Qu Biologics Begins Phase 2 Clinical Trial in Ulcerative Colitis

Jul 14, 2015

Enteris BioPharma Oral Formulation Progresses Into Phase 2 Study With Cara Therapeutics' CR845

Jul 13, 2015

C3 Jian Completes Second Phase 2 Clinical Trial of Anti-Cavity Drug

Jul 13, 2015

Allegro Ophthalmics Announces Positive Topline Results from Phase 2 Trial Evaluating Luminate in Patients with Vitreomacular Traction or Vitreomacular Adhesion

Jul 1, 2015

Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001

Jun 22, 2015

T3D Therapeutics, Inc. Receives FDA IND Approval to Begin Phase 2 Clinical Study of T3D-959 in Alzheimer's Patients

Jun 15, 2015

Milestone Pharmaceuticals Closes US$17 Million Series B Financing to Complete Phase 2 Clinical Studies for MSP-2017

Jun 12, 2015

Promedior Presents Additional Positive Phase 2 Data for PRM-151 in Myelofibrosis at EHA Annual Meeting

Jun 11, 2015

Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis

Jun 8, 2015

Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne

Jun 4, 2015

Promedior Announces Presentation of Additional Positive Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming Congress of the European Hematology Association

Jun 3, 2015

EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD)

May 27, 2015

Innocrin Pharmaceuticals, Inc. Initiates Phase 2 Castration-Resistant Prostate Cancer (CRPC) Study in Men Who Have Failed Enzalutmaide or Abiraterone

May 21, 2015

OrthoTrophix Completed Subject Enrollment of the Phase 2 Clinical Trial of a New Cartilage Repair Therapeutic for Knee Osteoarthritis

May 14, 2015

Adynxx Completes Patient Enrollment in Phase 2 Dose-Ranging Study of AYX1 for Prevention of Post-Surgical Pain

May 4, 2015

Allegro Ophthalmics Begins Phase 2 Clinical Study of Luminate for Non-Proliferative Diabetic Retinopathy

May 1, 2015

Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments

Apr 7, 2015

Madison Vaccines to Present at the 2015 World Vaccine Congress in Washington, D.C., on April 9th

Mar 24, 2015

NGM Biopharmaceuticals Announces Positive Phase 2 Clinical Data in Primary Biliary Cirrhosis Patients for NGM282, a First-in-Class Investigational Medicine

Mar 24, 2015

T3D Therapeutics, Inc. Awarded SBIR Phase 2 Grant From The National Institute On Aging For Alzheimer's Disease Drug Testing

Mar 11, 2015

AgeneBio Announces Publication of Phase 2 Clinical Trial Results for New Approach to Delaying the Onset of Alzheimer's Dementia

Mar 10, 2015

Madison Vaccines Announces Program Expansions for Its Investigational Prostate Cancer Vaccines

Feb 25, 2015

MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I

Feb 4, 2015

Qu Biologics Enrolls First Two Participants in Phase 2a Clinical Trial for Lung Cancer

Feb 2, 2015

Leading BioSciences Recieves FDA IND Clearance To Proceed With A Randomized, Multi-Center Phase 2 Clinical Trial Using LB1148 To Treat Septic Shock

Jan 20, 2015

Qu Biologics Launches Phase 2a Clinical Trial for Non-small Cell Lung Cancer (NSCLC)

Jan 12, 2015

Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND

Dec 22, 2014

ImmusanT Raises $12 Million in Series B Financing

Nov 17, 2014

OrthoTrophix Completed Patient Treatments in Part A of the Phase 2 Clinical Trial of a New Cartilage Repair Therapeutic for Knee Osteoarthritis and Initiated Patient Enrollment for Part B

Nov 13, 2014

Innocrin Pharmaceuticals and the Prostate Cancer Foundation (PCF) Join Forces for Innovative Phase 2 Clinical Study

Nov 7, 2014

Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73

Nov 6, 2014

Promedior Announces Presentation of Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming ASH Annual Meeting

Oct 29, 2014

Xcovery Raises $20M through Equity Investment from China’s Betta Pharmaceuticals for Development of ALK Inhibitor

Oct 16, 2014

Allegro Ophthalmics Begins Phase 2 Clinical Trial of Luminate (ALG-1001) for the Treatment of Diabetic Macular Edema

Sep 17, 2014

Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit

Sep 9, 2014

C3 Jian Completes Phase 2 Clinical Trial of Anti-Cavity Drug

Aug 4, 2014

Rebiotix Inc. Receives $25M for Series B Funding

Jun 30, 2014

Amunix Congratulates Versartis on Its Positive Phase 2a Results With VRS-317

Jun 24, 2014

EnGeneIC Unveils Clinical Development Strategy for EDV™ Nanocell Technology

Jun 23, 2014

Madison Vaccines Incorporated Announces Expansion of a Phase 2 Clinical Trial for MVI-816, Its Lead DNA Vaccine for Prostate Cancer

Jun 5, 2014

Promedior Announces Presentation of Interim Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming Congress of European Hematology Association

May 30, 2014

Promedior to Present Positive Preliminary Phase 2 Data for PRM-151 in Myelofibrosis at ASCO Annual Meeting

May 15, 2014

Promedior Announces Presentation of Interim Phase 2 Data on PRM-151 in Myelofibrosis at ASCO

Mar 7, 2014

C3 Jian Initiates Phase 2 Clinical Trial of Anti-Cavity Drug

Feb 20, 2014

OrthoTrophix Initiated Phase 2 Clinical Trial of a New Cartilage Repair Therapeutic for Knee Osteoarthritis and Closed Series A Financing

Feb 18, 2014

Sound Pharmaceuticals submits positive Phase 2 clinical trial data on SPI-1005 for the prevention and treatment of sensorineural hearing loss

Jan 13, 2014

Rebiotix Completes Enrollment in Phase 2 Clinical Trial of New Drug for the Treatment of Recurrent Clostridium difficile-Associated Diarrhea

Jan 8, 2014

Promedior Attains Patient Enrollment Milestone in Phase 2 Clinical Study of PRM-151 in Myelofibrosis

Dec 19, 2013

MicuRx Expands Global Clinical Trial Program For Oral Antibiotic MRX-I

Dec 9, 2013

Neuraltus Pharmaceuticals' NP001 Phase 2 Results Highlighted at the 24th International Symposium on ALS/MND

Nov 11, 2013

Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma

Nov 5, 2013

Sound Pharmaceuticals successfully completes its first Phase 2 clinical trial with SPI-1005 involving iPod® or noise induced hearing loss

Nov 5, 2013

Sound Pharmaceuticals successfully completes its first Phase 2 clinical trial with SPI-1005 involving iPod or noise induced hearing loss

Oct 23, 2013

Alzheon Launches with Veteran Team and Funding to Accelerate Drug Development in Alzheimer’s Disease and Other Neurodegenerative Disorders

Oct 9, 2013

Promedior Initiates Phase 2 Clinical Study of PRM-151 in Myelofibrosis

Sep 10, 2013

Theraclone Sciences Announces Initiation of Phase 2a Trial of TCN-202 for the Prevention of Human Cytomegalovirus Infection

Sep 8, 2013

Theraclone Sciences Announces Universal Therapeutic Antibody for Influenza A Demonstrates Reductions in Clinical Symptoms Score and Viral Load in a Phase 2a Human Viral Challenge Study

Sep 5, 2013

Adynxx Completes Patient Enrollment in Phase 2 Clinical Study of Lead Therapeutic for Prevention of Pain, AYX1

Jul 29, 2013

Rebiotix Receives FDA IND Approval to Begin Phase 2 Trial of Pioneering Microbiota Restoration Therapy

Jul 26, 2013

CereSpir Incorporated is Pleased With Positive Interim Phase 2 Results for CHF 5074 in Patients With Mild Cognitive Impairment, Presented by Chiesi at the AAIC 2013 Meeting in Boston

Mar 27, 2013

CureVac Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with Castration-Resistant Prostate Cancer

Mar 27, 2013

CureVac beginnt klinische Phase 2b Studie seines mRNA-basierten Krebsimpfstoffs bei Patienten mit kastrationsresistentem Prostatakrebs

Feb 18, 2013

Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia USA - English USA - English

Nov 20, 2012

Atox Bio Announces Positive Top Line Results in the AB103 Necrotizing Soft Tissue Infections (NSTI) Phase 2a Trial

Oct 30, 2012

Neuraltus Pharmaceuticals Announces Phase 2 Clinical Results for NP001 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Oct 25, 2012

Theraclone Sciences Initiates Phase 2 Viral Challenge Clinical Study of Therapeutic Antibody for the Treatment of Influenza A

Sep 10, 2012

FDA grants Fast Track designation to Atox Bio’s AB103 for the treatment of necrotizing soft tissue infections (NSTI)

Sep 5, 2012

Lead Therapeutic Candidate for Treatment of Pain from Adynxx, AYX1, Well-Tolerated in Phase 1 Clinical Study

Aug 22, 2012

Symphogen Publishes Final Rozrolimupab (SYM001) Phase 2 Trial Results in ITP in BLOOD Journal

Feb 14, 2012

Biogen Idec to Acquire Stromedix

Dec 19, 2011

Atox Bio Raises $3.25 million to Advance Development of AB103, a Novel Therapy for the Treatment of Severe Bacterial Infections, Currently in Phase 2 Clinical Trials

Dec 12, 2011

Symphogen Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at ASH

Oct 21, 2011

Romark Announces Clinical Trial Results for New Influenza Drug Presented at IDSA Meeting 2011

Sep 12, 2011

Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes

Aug 23, 2011

Symphogen Announces Initiation of Phase 2 Trial of Sym004 EGFR Antibody Mixture in Patients with Squamous Cell Carcinoma of Head and Neck Cancer

Jun 28, 2011

Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions

Jun 10, 2011

Symphogen Presents Preliminary Results from Phase 2 Clinical Trial with Rozrolimupab at the Annual European Hematology Association

Mar 21, 2011

Silence Therapeutics' Partner Quark Pharmaceuticals Announces Results From Phase 2 PF-04523655 Study in Diabetic Macular Edema

Sep 22, 2010

Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD

Jun 28, 2010

Intarcia Therapeutics, Inc. Presents Positive ITCA 650 Phase 2 Study Results as a Late-Breaker at the American Diabetes Association 70th Scientific Sessions